



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2533423 C 2014/07/22

(11)(21) **2 533 423**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2004/07/23
(87) Date publication PCT/PCT Publication Date: 2005/02/10
(45) Date de délivrance/Issue Date: 2014/07/22
(85) Entrée phase nationale/National Entry: 2006/01/23
(86) N° demande PCT/PCT Application No.: GB 2004/003235
(87) N° publication PCT/PCT Publication No.: 2005/012524
(30) Priorité/Priority: 2003/07/25 (GB0317466.1)

(51) Cl.Int./Int.Cl. *C12N 15/11* (2006.01),
A61K 38/00 (2006.01)
(72) Inventeur/Inventor:
HELLEDAY, THOMAS, SE
(73) Propriétaire/Owner:
THE UNIVERSITY OF SHEFFIELD, GB
(74) Agent: KIRBY EADES GALE BAKER

(54) Titre : UTILISATION D'ARNI INHIBITEUR DE L'ACTIVITE PARP POUR LA FABRICATION D'UN MEDICAMENT
POUR LE TRAITEMENT DU CANCER
(54) Title: USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE
TREATMENT OF CANCER

(57) **Abrégé/Abstract:**

The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/012524 A1

(51) International Patent Classification⁷: C12N 15/11,
A61K 38/00

(21) International Application Number:
PCT/GB2004/003235

(22) International Filing Date: 23 July 2004 (23.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0317466.1 25 July 2003 (25.07.2003) GB

(71) Applicant (for all designated States except US): **THE UNIVERSITY OF SHEFFIELD** [GB/GB]; Western Bank, Sheffield S10 2TN (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **HELLEDAY, Thomas** [SE/SE]; Erik Dahlbergsgatan 38, S-115 32 Stockholm (SE).

(74) Agent: **HARRISON GODDARD FOOTE**; 31 St. Saviourgate, York YO1 8NQ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER

(57) Abstract: The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.

WO 2005/012524 A1

USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE
TREATMENT OF CANCER

This invention relates to the use of an agent that inhibits the activity of an enzyme which mediates the repair of DNA strand breaks in the treatment of certain forms of
5 cancer in particular breast cancer.

Homologous recombination (HR) has been shown to play an important role in repair of damage occurring at DNA replication forks in mammalian cells (2). Thus, cells deficient in HR show retarded growth and exhibit higher level of genetic instability. It
10 is believed that genetic instability due to loss of HR repair in human cancers significantly contributes to the development of cancer in these cells (1).

Post transcriptional modification of nuclear proteins by poly(ADP-ribosyl)ation (PARP) in response to DNA strand breaks plays an important role in DNA repair,
15 regulation of apoptosis, and maintenance of genomic stability.

Poly(ADP-ribose) Polymerase (PARP-1) is an abundant nuclear protein in mammalian cells that catalyses the formation of poly(ADP-ribose) (PAR) polymers using NAD^+ as substrate. Upon DNA damage, PARP-1 binds rapidly to a DNA
20 strand break (single strand or double strand) and catalyses the addition of negatively charged PAR chains to itself (automodification) and other proteins (see [3, 4] for reviews). The binding of PARP-1 to DNA strand breaks is believed to protect DNA lesions from further processing until PARP-1 is dissociated from the break by the accumulated negative charge resulting from PAR polymers (5,6).

25 Although PARP-1 has been implicated in several nuclear processes, such as modulation of chromatin structure, DNA replication, DNA repair and transcription, PARP-1 knockout mice develop normally (7). Cells isolated from these mice exhibit a hyper recombination phenotype and genetic instability in the form of increased
30 levels of SCE, micronuclei and tetraploidy (8-10). Genetic instability may also occur in these PARP-1 knockout mice through telomere shortening, increased frequency of chromosome fusion and aneuploidy (11), although all of these results could not be repeated in another set of PARP-1 knock-out mice (12). In the former mice knockout, PARP-1 null mutation rescue impaired V(D)J recombination in SCID mice (13).

- These results support the view suggested by Lindahl and coworkers that PARP-1 has a protective role against recombination (5). They proposed that binding of PARP-1 to DNA strand breaks prevents the recombination machinery from recognizing and processing DNA lesions or, alternatively, that the negative charges accumulated following poly ADP-ribosylation repel adjacent recombinogenic DNA sequences. Only the latter model is consistent with inhibition of PARP-1 itself and expression of a dominant negative mutant PARP-1, inducing SCE, gene amplification and homologous recombination (HR [14-18]).
- 10 Studies based on treating cells with PARP inhibitors or cells derived from PARP-1 or PARP-2 knockout mice indicate that the suppression of PARP-1 activity increases cell susceptibility to DNA damaging agents and inhibits strand break rejoining (3, 4, 8-11, 19, 20, 47).
- 15 Inhibitors of PARP-1 activity have been used in combination with traditional anti-cancer agents such as radio therapy and chemotherapy (21). The inhibitors were used in combination with methylating agents, topoisomerase poisons and ionising radiations and were found to enhance the effectiveness of these forms of treatment. Such treatments, however, are known to cause damage and death to non cancerous or
- 20 "healthy" cells and are associated with unpleasant side effects.

There is therefore a need for a treatment for cancer that is both effective and selective in the killing of cancer cells and which does not need to be administered in combination with radio or chemotherapy treatments.

- 25 The present inventors have surprisingly found that cells deficient in homologous recombination (HR) are hypersensitive to PARP inhibitors as compared to wild type cells. This is surprising since PARP-1 knockout mice live normally thereby indicating that PARP-1 is not essential for life. Thus, it could not be expected that
- 30 cells would be sensitive to PARP inhibition.

SUMMARY OF THE INVENTION

In one particular embodiment there is provided use of a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor in the manufacture of a medicament for the treatment of cancer cells
 5 defective in homologous recombination, wherein the cancer cells have a defect in a gene which mediates homologous recombination selected from the group consisting of XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA,
 10 FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1 and RAD9.

In another particular embodiment there is provided use of a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor for the treatment of cancer cells defective in homologous recombination, wherein the cancer cells have a defect in a gene which
 15 mediates homologous recombination selected from the group consisting of XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1 and RAD9.

20

According to a first aspect of the invention there is provided the use of an agent that inhibits the activity of an enzyme that mediates the repair of DNA strand breaks in the

manufacture of a medicament for the treatment of diseases that are caused by a genetic defect in a gene that mediates homologous recombination.

5 In a further aspect the invention provides a method of treatment of a disease or condition in a mammal, including human, which is caused by a genetic defect in a gene which mediates homologous recombination, which method comprises administering to the mammal a therapeutically effective amount of an agent which inhibits the activity of an enzyme which mediates repair of DNA strand breaks or other lesions present at replication forks.

10

In a preferred aspect said enzyme is PARP. In a further preferred aspect said agent is a PARP inhibitor or an RNAi molecule specific to PARP gene.

In a further preferred aspect, the use is in the treatment of cancer.

15

Preferably the medicament is a pharmaceutical composition consisting of the PARP inhibitor in combination with a pharmaceutically acceptable carrier or diluent.

20

The specific sensitivity of HR defective tumours to PARP-1 inhibition means that normally dividing cells in the patient will be unaffected by the treatment. Treatment of HR defective cancer cells using a PARP inhibitor also has the advantage that it does not need to be administered as a combination therapy along with conventional radio or chemotherapy treatments thereby avoiding the side effects associated with these conventional forms of treatment.

25

A genetic defect in a gene which mediates homologous recombination may be due to a mutation in, the absence of, or defective expression of, a gene encoding a protein involved in HR.

30

In a further aspect, the invention further provides the use of a PARP inhibitor in the manufacture of a medicament for inducing apoptosis in HR defective cells.

In another aspect the invention provides a method of inducing apoptosis in HR defective cells in a mammal which method comprises administering to the mammal a therapeutically effective amount of a PARP inhibitor.

- 5 By causing apoptosis in HR defective cells it should be possible to reduce or halt the growth of a tumour in the mammal.

Preferably, the HR defective cells are cancer cells.

- 10 Cancer cells defective in HR may partially or totally deficient in HR. Preferably the cancer cells are totally deficient in HR.

The term "cancer" or "tumour" includes lung, colon, pancreatic, gastric, ovarian, cervical, breast or prostate cancer. The cancer may also include skin, renal, liver,
15 bladder or cerebral cancer. In a preferred aspect, the cancer is in a mammal, preferably human.

The cancer to be treated may be an inherited form of cancer wherein the patient to be treated has a familial predisposition to the cancer. Preferably, the cancer to be treated
20 is gene-linked hereditary cancer. In a preferred embodiment of the invention the cancer is gene-linked hereditary breast cancer.

In a preferred aspect, the PARP inhibitor is useful in the treatment of cancer cells defective in the expression of a gene involved in HR. Genes with suggested function in
25 HR include XRCC1, ADPRT (PARP-1), ADPRTL2 (PARP-2), CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1,
30 Mus81, Eme1, DDS1, BARD (see (2, 3, 5, 22-28) for reviews).

A gene involved in HR may be a tumour suppressor gene. The invention thus provides for the treatment of cancer cells defective in the expression of a tumour suppressor gene. Preferably, the tumour suppressor gene is BRCA1 or BRCA2.

Breast cancer is the most common cancer disease among women in the Western world today. Certain families have strong predisposition for breast cancer, which is often owing to an inherited mutation in one allele of either BRCA1 or BRCA2. However, 5 these patients still maintain one functional allele. Thus, these patients develop normally and have no phenotypic consequence from this mutation. However, in one cell, the functional allele might be lost, making this cell cancerous and at the same time deficient in homologous recombination (HR). This step is critical for the onset of a tumour (1).

10

The present inventors have surprisingly found that BRCA2 deficient cells are 100 times more sensitive to the cytotoxicity of the PARP inhibitor, NU1025, than wild type cells.

15 Thus in a preferred aspect, the invention provides the use of a PARP inhibitor in the manufacture of a medicament for the treatment of cancer cells defective in HR, e.g due to the loss of BRCA1 and/or BRCA2 expression.

The cancer cells to be treated may be partially or totally deficient in BRCA1 or BRCA2 20 expression. BRCA1 and BRCA2 mutations can be identified using multiplex PCR techniques, array techniques (29, 30) or using other screens known to the skilled person.

PARP inhibitors useful in the present invention may be selected from inhibitors of PARP-1, PARP-2, PARP-3, PARP-4, tankyrase 1 or tankyrase 2 (see 31 for a review).

25 In a preferred embodiment, the PARP inhibitor useful in the present invention is an inhibitor of PARP-1 activity.

PARP inhibitors useful in the present invention include benzimidazole-carboxamides, quinazolin-4-[3H]-ones and isoquinoline derivatives (e.g. 2-(4- 30 hydroxyphenyl)benzimidazole-4-carboxamide (NU1085), 8-hydroxy-2-methylquinazolin-4-[3H]one (NU1025); 6(5H)phenanthridinone; 3 aminobenzamide; benzimidazole-4-carboxamides (BZ1-6) and tricyclic lactam indoles (TI1-5) [32]. Further inhibitors of PARP may be identified either by design [33] or the novel FlashPlate assay [34].

The PARP inhibitor formulated as a pharmaceutical composition may be administered in any effective, convenient manner effective for targeting cancer cells including, for instance, administration by oral, intravenous, intramuscular, intradermal, intranasal, 5 topical routes among others. Carriers or diluents useful in the pharmaceutical composition may include, but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof.

10 In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion. The inhibitor may be administered directly to a tumour or may be targeted to the tumour via systemic administration.

15 A therapeutically effective amount of the inhibitor is typically one which is sufficient to achieve the desired effect and may vary according to the nature and severity of the disease condition, and the potency of the inhibitor. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease.

20 For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be up to 100mg/kg, for example from 0.01mg/kg to 50 mg/kg body weight, typically up to 0.1, 0.5, 1.0, 2.0 5.0, 10, 15, 20 or 30mg/kg body weight. Ultimately, however, the amount of inhibitor administered and the frequency of administration will be at the discretion of a physician.

25

A therapeutic advantage of using PARP inhibitors to treat cancer cells is that only very low doses are needed to have a therapeutic effect in treating cancer thereby reducing systemic build up of the inhibitors and any associated toxic effects.

30 A preferred aspect of the invention provides an agent which is an inhibitory RNA (RNAi) molecule.

A technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as inhibitory RNA (RNAi), into a cell which results in

the destruction of mRNA complementary to the sequence included in the RNAi molecule. The RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. The RNAi molecule is typically derived from exonic or coding
 5 sequence of the gene which is to be ablated.

Preferably said RNAi molecule is derived from the nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

- a) a nucleic acid sequence as represented by the sequence in Figure 9, 10, 11,
 10 12, 13 or 14 or fragment thereof;
- b) a nucleic acid sequence which hybridises to the nucleic acid sequences of Figure 9, 10, 11, 12, 13 or 14 and encodes a gene for PARP;
- c) a nucleic acid sequence which comprise sequences which are degenerate
 15 as a result of the genetic code to the nucleic acid sequences defined in (a) and (b).

Recent studies suggest that RNAi molecules ranging from 100-1000bp derived from coding sequence are effective inhibitors of gene expression. Surprisingly, only a few molecules of RNAi are required to block gene expression which implies the
 20 mechanism is catalytic. The site of action appears to be nuclear as little if any RNAi is detectable in the cytoplasm of cells indicating that RNAi exerts its effect during mRNA synthesis or processing.

More preferably said RNAi molecule according has a length of between 10 nucleotide
 25 bases (nb) –1000nb. Even more preferably said RNAi molecule has a length of 10nb; 20nb; 30nb; 40nb; 50nb; 60nb; 70nb; 80nb; 90nb; or 100bp. Even more preferably still said RNAi molecule is 21nb in length.

Even more preferably still the RNAi molecule comprises the nucleic acid sequence
 30 aaa agc cau ggu gga gua uga (PARP-1)

Even more preferably still the RNAi molecule consists of the nucleic acid sequence
 aag acc aau cuc ucc agu uca ac (PARP-2)

Even more preferably still the RNAi molecule consists of the nucleic acid sequence
aag acc aac auc gag aac aac (PARP-3)

The RNAi molecule may comprise modified nucleotide bases.

5

Preferred features of each aspect of the invention are as for each of the other aspects
mutatis mutandis.

10 The present invention will now be described by way of example only with reference
to the accompanying figures, wherein:

Figure 1 is a graph demonstrating that HR deficient cells are hypersensitive to the
toxic effect caused by inhibition of PARP-1. Colony outgrowth of the Chinese
hamster cell lines AA8 (wild-type), irs1SF (deficient in HR[4]), CXR3 (irs1SF
15 complemented with XRCC3 [2]), V79 (wild-type), irs1 (deficient in HR[5]) or
irs1X2.2 (irs1 complimented with XRCC2 [1]) upon exposure to 3-AB (A), ISQ (B)
or NU1025 (C). The means (symbols) and standard deviation (bars) of at least three
experiments are shown. Colony outgrowth assay was used;

20 Figure 2 is a graph showing cell survival in the presence of PARP inhibitor NU1025
in wt V79 cells, BRCA2 deficient VC-8 cells and VC-8 cells complimented with
functional BRCA2 gene (VC-8#13, VC-8+B2). Colony outgrowth assay was used;

25 Figure 3 is a histogram showing the percentage of the cells in apoptosis following a
72 hour incubation with NU1025;

Figure 4. (a) Western blot analysis of protein lysates isolated from MCF-7 (p53^{wt}) or
MDA-MB-231 (p53^{mut}) breast cancer cells following 48 hours transfection with
siRNA. (b) Colony outgrowth of siRNA-treated MCF-7 cells or (c) MDA-MB-231
30 cells following exposure to the PARP inhibitor NU1025. The means (symbols) and
standard deviation (bars) of at least three experiments are shown.

Figure 5. BRCA2 deficient cells fail to repair a recombination lesion formed at
replication forks by inhibitors of PARP. (a) Visualization of double strand breaks

(DSBs) in BRCA2 proficient or deficient cells following a 24-hour treatment with NU1025 (0.1 mM) by pulse-field gel electrophoresis. Hydroxyurea 2 mM was used as a positive control. (b) Visualisation of γ H2Ax foci in untreated V-C8+B2 and V-C8 cells. Number of cells containing γ H2Ax foci (c) or RAD51 foci (d) visualised in V-C8+B2 and V-C8 cells following a 24-hour treatment with NU1025 (10 μ M). The means (symbols) and standard errors (bars) of three to nine experiments are shown. (e) A suggested model for cell death induced in BRCA2 deficient cells.

Figure 6. PARP-1 and not PARP-2 is important in preventing formation of a recombinogenic lesion, causing death in absence of BRCA2. (a) RT-PCR on RNA isolated from SW480SN.3 cells treated with BRCA2, PARP-1 and PARP-2 siRNA in combinations as shown for 48 hours. (b) Clonogenic survival following 48-hours depletion of BRCA2, PARP-1 and PARP-2. The means (symbols) and standard deviation (bars) of at least three experiments are shown. Two and three stars designate statistical significance in *t-test* $p < 0.01$ and $p < 0.001$, respectively. (c) Western blot for PARP-1 in SW480SN.3 cells treated with different siRNA.

Figure 7. (a) Visualisation of PAR polymers in untreated and (b) thymidine treated V79 cells (5 mM for 24 hours). (c) Percentage cells containing >10 sites of PARP activity following treatment with hydroxyurea (0.2 mM) and thymidine (5 mM). At least 300 nuclei were counted for each treatment and experiment. (d) Survival of V-C8+B2 cells following co-treatment with hydroxyurea or (e) thymidine and NU1025 (10 μ M). (f) The activity of PARP was measured by the level of free NAD(P)H¹¹, following treatment with MMS, hydroxyurea (0.5 mM) or thymidine (10 mM). The means (symbol) and standard deviation (error bars) from at least three experiments are depicted.

Figure 8. (a) Visualisation of PAR polymers in untreated V-C8 and (b) V-C8+B2 cells. (c) Quantification of percentage cells containing >10 sites of PARP activity in untreated V-C8 and V-C8+B2 cells. (d) Level of NAD(P)H measured in untreated V-C8 and V-C8+B2 cells. Three stars designate $p < 0.001$ in *t-test*. (e) Visualization of RAD51 and sites of PARP activity in V79 cells following a 24-hour thymidine

treatment (5 mM). (f) A model for the role of PARP and HR at stalled replication forks.

Figure 9 is the human cDNA sequence of PARP-1;

5

Figure 10 is the human cDNA sequence of PARP-2;

Figure 11 is the human cDNA sequence of PARP-3;

10 Figure 12 is the human gDNA sequence of Tankyrase 1;

Figure 13 is the human mRNA sequence of Tankyrase 2;

Figure 14 is the human mRNA sequence of VPARP.

15

Materials and Methods

Cytotoxicity of PARP inhibitors to HR-defective cells: XRCC2, XRCC3 or BRCA2

Cell culture

The irs1, irs1X2.1 and V79-4 cell lines were a donation from John Thacker [40] and the AA8, irs1SF and CXR3 cell lines were provided by Larry Thompson [41].

25 The VC-8, VC-8+B2, VC-8#13 were a gift from Malgorzata Zdzienicka [42]. All cell lines in this study were grown in Dulbecco's modified Eagle's Medium (DMEM) with 10% Foetal bovine serum and penicillin (100 U/ml) and streptomycin sulphate (100 µg/mL) at 37°C under an atmosphere containing 5% CO₂.

Toxicity assay - colony outgrowth assay

30 500 cells suspended in medium were plated onto a Petri dish 4 hours prior to the addition of 3-AB, ISQ or NU1025. ISQ and NU1025 were dissolved in DMSO to a final concentration of 0.2% in treatment medium. 7 - 12 days later, when colonies could be observed, these colonies were fixed and stained with methylene blue in

methanol (4 g/l). Colonies consisting of more than 50 cells were subsequently counted.

Apoptosis experiments

5 0.25x10⁶ cells were plated onto Petri dishes and grown for 4 hours before treatment with NU1025. After 72 hours, cells were trypsinized and resuspended with medium containing any floating cells from that sample. The cells were pelleted by centrifugation and resuspended for apoptosis analysis with FITC-conjugated annexin-V and propidium iodine (PI) (ApoTarget, Biosource International) according to
10 manufacturer's protocol. Samples were analysed by flow cytometry (Becton-Dickenson FACSsort, 488 nm laser), and percentage of apoptotic cells was determined by the fraction of live cells (PI-negative) bound with FITC-conjugated annexin-V.

15 Immunofluorescence

Cells were plated onto coverslips 4 h prior to 24-h treatments as indicated. Following treatments the medium was removed and coverslips rinsed once in PBS at 37°C and fixed as described elsewhere [2]. The primary antibodies and dilutions used in this study were; rabbit polyclonal anti PAR (Trevigen; 1:500), goat polyclonal anti Rad51
20 (C-20, Santa Cruz; 1:200) and rabbit polyclonal anti Rad51 (H-92, Santa Cruz; 1:1000). The secondary antibodies were Cy-3-conjugated goat anti-rabbit IgG antibody (Zymed; 1:500), Alexa 555 goat anti-rabbit F(ab')₂ IgG antibody (Molecular Probes; 1:500), Alexa 546 donkey anti-goat IgG antibody (Molecular Probes; 1:500) and Alexa 488 donkey anti-rabbit IgG antibody (Molecular Probes; 1:500).
25 Antibodies were diluted in PBS containing 3% bovine serum albumin. DNA was stained with 1 µg/ml To Pro (Molecular Probes). Images were obtained with a Zeiss LSM 510 inverted confocal microscope using planapochromat 63X/NA 1.4 oil immersion objective and excitation wavelengths 488, 546 and 630 nm. Through focus maximum projection images were acquired from optical sections 0.50 µm apart
30 and with a section thickness of 1.0 µm. Images were processed using Adobe PhotoShop (Abacus Inc). At least 300 nuclei were counted on each slide and those containing more than 10 RAD51 foci or sites of PARP activity were classified as positive.

PARP activity assays

A water-soluble tetrazolium salt (5mM WST-8) was used to monitor the amount of NAD(P)H through its reduction to a yellow coloured formazan dye[43]. 5000 cells were plated in at least triplicate into wells of a 96 well plate and cultured in 100µl normal growth media for 4 h at 37°C. CK8 buffer (Dojindo Molecular Technology, Gaithersburg, USA), containing WST-8, was then added either with or without treatment with DNA damaging agents at concentrations indicated. Reduction of WST-8 in the presence of NAD(P)H was determined by measuring visible absorbance (OD₄₅₀) every 30 min. A medium blank was also prepared containing just media and CK8 buffer. Changes in NAD(P)H levels were calculated by comparing the absorbance of wells containing cells treated with DNA damaging agents and those treated with DMSO alone. Alternately relative levels of NAD(P)H in different cells lines were calculated after 4 h incubation in CK8 buffer.

The ability of NU1025 to inhibit PARP-1 activity was also assayed in permeabilised cells using a modification of the method of Halldorsson *et al* [44], and described in detail elsewhere [45]. Briefly: 300 µl of NU1025-treated (15 min) permeabilised cells were incubated at 26°C with oligonucleotide (final conc. 2.5 µg/ml), 75 µM NAD + [³² P] NAD (Amersham Pharmacia, Amersham, UK) in a total volume of 400 µl. The reaction was terminated after 5 min by adding ice cold 10%TCA 10%Na Ppi for 60 min prior to filtering through a Whatman GF/C filter (LabSales, Maidstone, UK), rinsed 6x with 1% TCA 1% NaPPi, left to dry and incorporated radioactivity was measured to determine PARP-1 activity. Data are expressed as pmol NAD incorporated/10⁶ cells by reference to [³² P] NAD standards.

Pulse-field gel electrophoresis

1.5x10⁶ cells were plated onto 100 mm dishes and allowed 4 h for attachment. Exposure to drug was for 18 h after which cells were trypsinised and 10⁶ cells melted into each 1% agarose insert. These inserts were incubated as described elsewhere (8) and separated by pulse-field gel electrophoresis for 24 h (BioRad; 120° angle, 60 to 240 s switch time, 4 V/cm). The gel was subsequently stained with ethidium bromide for analysis.

Predesigned BRCA2 SMARTpool and scrambled siRNAs were purchased (Dharmacon, Lafayette, CO). 10000 cells seeded onto 6 well plates and left over night before transfected with 100nM siRNA using Oligofectamine Reagent (Invitrogen) according to manufacturers instructions. Cells were then cultured in normal growth media for 48 h prior to trypsinisation and replating for toxicity assays. Suppression of BRCA2 was confirmed by Western blotting (as described previously [46]) of protein extracts treated with siRNA with an antibody against BRCA2 (Oncogene, Nottingham, UK).

10

EXAMPLES

Homologous recombination deficient cells are hypersensitive to PARP-1 inhibition

To investigate the involvement of HR in cellular responses to inhibition of PARP-1, the effects of PARP-1 inhibitors on the survival of HR repair deficient cell lines were studied. It was found that cells deficient in HR (i.e., *irs1SF* which is defective in *XRCC3* or *irs1* which is defective in *XRCC2* [see Table 1] were very sensitive to the toxic effect of 3-aminobenzamide (3-AB) and to two more potent inhibitors of PARP-1: 1,5-dihydroxyisoquinoline (ISQ; [37]) or 8-hydroxy-2-methylquinazolinone (NU1025 [38, 39]) (Figure 1). The sensitivity in *irs1SF* cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional *XRCC3* gene (*CXR3*). Similarly, the sensitivity in *irs1* cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional *XRCC2* gene (*irs1X2.2*).

BRCA2 deficient cells are hypersensitive to PARP-1 inhibition

The survival of BRCA2 deficient cells (VC8) and wild type cells (V79Z) in the presence of inhibitors of PARP-1 was investigated. It was found that VC8 cells are very sensitive to the toxic effect of NU1025 (Figure 2). The sensitivity in VC8 cells was corrected by the introduction of a functional BRCA2 gene either on chromosome 13 (VC8#13) or on an overexpression vector (VC8+B2). This result demonstrates that the sensitivity to PARP-1 inhibitors is a direct consequence of loss of the BRCA2 function.

To investigate if inhibition of PARP-1 triggers apoptosis in BRCA2 deficient cells, the level of apoptosis 72 hours following exposure to NU1025 was investigated. It was found that NU1025 triggered apoptosis only in VC8 cells, showing that loss of PARP-1 activity in BRCA2 deficient cells triggers this means of death (Figure 3).

5

BRCA2 deficient breast cancer cells are hypersensitive to PARP-1 inhibition

It was examined whether the MCF7 (wild-type p53) and MDA-MB-231 (mutated p53) breast cancer cell lines displayed a similar sensitivity to NU1025 upon depletion of BRCA2. It was found that PARP inhibitors profoundly reduced the survival of MCF7 and MDA-MB-231 cells only when BRCA2 was depleted with a mixture of BRCA2 siRNA (Figure 4). This shows that BRCA2 depleted breast cancer cells are sensitive to PARP inhibitors regardless of p53 status.

BRCA2 deficient cells die from PARP-1 inhibition in absence of DNA double-strand breaks (DSBs) but in presence of γ H2Ax

HR is known to be involved in the repair of DSBs and other lesions that occur during DNA replication [2]. To determine whether the sensitivity of BRCA2 deficient cells is the result of an inability to repair DSBs following NU1025 treatment, the accumulation of DSBs in V79 and V-C8 cells was measured following treatments with highly toxic levels of NU1025. It was found that no DSBs were detectable by pulsed field gel electrophoretic analysis of DNA obtained from the treated cells (Figure 5A), suggesting that low levels of DSBs or other recombinogenic substrates accumulated following PARP inhibition in HR deficient cells, which trigger γ H2Ax (Figure 5B). The reason why BRCA2 deficient cells die following induction of these recombinogenic lesions is likely to be due to an inability to repair such lesions. To test this, the ability of BRCA2 deficient V-C8 cells and BRCA2 complimented cells to form RAD51 foci in response to NU1025 was determined. It was found that RAD51 foci were indeed induced in V-C8+B2 cells following treatment with NU1025 (statistically significant in *t-test* $p < 0.05$; Figure 5D). This indicates that the recombinogenic lesions trigger HR repair in these cells allowing them to survive. In contrast, the BRCA2 deficient V-C8 cells were unable to form RAD51 foci in response to NU1025 treatment (Figure 5D) indicating no HR, which would leave the recombinogenic lesions unrepaired and thus cause cell death.

PARP-1 and not PARP-2 is important in preventing formation of a recombinogenic lesion

There are two major PARPs present in the nucleus in mammalian cells, PARP-1 and PARP-2 and all reported PARP inhibitors inhibit both. In order to distinguish which PARP was responsible for the effect, we tested if the absence of PARP-1 and/or PARP-2 results in accumulation of toxic lesions, by depleting these and BRCA2 with siRNA in human cells (Figure 6a). We found that the clonogenic survival was significantly reduced when both PARP-1 and BRCA2 proteins were co-depleted from human cells (Figure 6b). Depletion of PARP-2 with BRCA2 had no effect on the clonogenic survival and depletion of PARP-2 in PARP-1 and BRCA2 depleted cells did not result in additional toxicity. These results suggest that PARP-1 and not PARP-2 is responsible for reducing toxic recombinogenic lesions in human cells. The cloning efficiency was only reduced to 60% of control in PARP-1 and BRCA2 co-depleted cells, while no HR deficient cells survived treatments with PARP inhibitors. This is likely to do with incomplete depletion of the abundant PARP-1 protein by siRNA (Figure 6c), which might be sufficient to maintain PARP-1 function in some of the cells.

PARP-1 is activated by replication inhibitors

HR is also involved in repair of lesions occurring at stalled replication forks, which may not involve detectable DSBs [2]. To test if PARP has a role at replication forks, PARP activation in cells treated cells with agents (thymidine or hydroxyurea) that retard or arrest the progression of DNA replication forks was examined. Thymidine depletes cells of dCTP and slows replication forks without causing DSBs. Hydroxyurea depletes several dNTP and block the replication fork, which is associated with the formation of DSBs at replication forks [2]. Both of these agents potently induce HR [2]. V79 hamster cells treated for 24 hours with thymidine or hydroxyurea were stained for PAR polymers. This revealed a substantial increase in the number of cells containing sites of PARP activity (Figure 7C). This result suggests a function for PARP at stalled replication forks. It was also shown that inhibition of PARP with NU1025 enhances the sensitivity to thymidine or hydroxyurea in V-C8+B2 cells (Figure 7D,E). This result suggests that PARP activity is important in

repair of stalled replication forks or alternatively that it prevents the induction of death in cells with stalled replication forks.

PARP is rapidly activated at DNA single-strand breaks (SSB) and attracts DNA repair enzymes [3-6]. Methylmethane sulphonate (MMS) causes alkylation of DNA, which is repaired by base excision repair. PARP is rapidly activated by the SSB-intermediate formed during this repair, which depletes the NAD(P)H levels (Figure 7F). We found that the activation of PARP and reduction of NAD(P)H levels is much slower following thymidine or hydroxyurea treatments. This slow PARP activation can be explained by the indirect action of thymidine and hydroxyurea and the time required to accumulate stalled replication forks as cells enter the S phase of the cell cycle.

PARP-1 and HR have separate roles at stalled replication forks

The number sites of PARP activity in untreated BRCA2 deficient V-C8 cells was determined. It was found that more V-C8 cells contain sites of PARP activity compared to V-C8+B2 cells (Figure 8A,B,C). Also, the V-C8 cells have lower free NAD(P)H levels than the corrected cells (Figure 8D), as a likely result of the increased PARP activity. Importantly these sites of PARP activity do not overlap with RAD51 foci (Figure 8E).

The results herein suggest that PARP and HR have separate roles in the protection or rescue of stalled replication forks (Figure 8F). A loss of PARP activity can be compensated by increased HR while a loss of HR can be compensated by increased PARP activity. However, loss of both these pathways leads to accumulation of stalled replication forks and to death, as in the case of PARP inhibited BRCA2 deficient cells.

As shown in the model outlined in Figure 8F PARP and HR have complementary roles at stalled replication forks. (i) Replication forks may stall when encountering a roadblock on the DNA template. In addition, they may also stall temporarily, due to lack of dNTPs or other replication co-factors. (ii) PARP binds stalled replication forks or other replication-associated damage, triggering PAR polymerization. Resulting negatively charged PAR polymers may protect stalled replication forks, by repelling

proteins that normally would process replication forks (e.g., resolvases), until the replication fork can be restored spontaneously when dNTPs or other co-factors become available. Alternatively, PAR polymers or PARP may attract proteins to resolve the replication block by other means. (iii) In absence of PARP activity, HR
 5 may be used as an alternative pathway to repair stalled replication forks. This compensatory model explains the increased level of HR and RAD51 foci found in PARP deficient cells³⁻⁵ and higher PARP activity found in HR deficient cells (i.e. V-C8). Spontaneous replication blocks/lesions are only lethal in the absence of both PARP and HR.

10

Table 1. Genotype and origin of cell lines used in this study.

Cell line	Genotype	Defect	Origin	Reference
AA8	Wt	Wt	CHO	[41]
irs1SF	<i>XRCC3</i> ⁻	<i>XRCC3</i> ⁻ , deficient in HR	AA8	[41]
CXR3	<i>XRCC3</i> ⁻ + <i>hXRCC3</i>	Wt	irs1SF	[41]
V79-4	Wt	Wt	V79	[40]
irs1	<i>XRCC2</i> ⁻	<i>XRCC2</i> ⁻ , deficient in HR	V79-4	[40]
irs1X2.2	<i>XRCC2</i> ⁻ + <i>hXRCC2</i>	Wt	irs1	[40]
V79-Z	Wt	Wt	V79	[42]
VC8	<i>BRCA2</i> ⁻	<i>BRCA2</i> ⁻ , deficient in HR	V79-Z	[42]
VC8#13	<i>BRCA2</i> ⁻ + <i>hBRCA2</i>	Wt	VC8	[42]
VC8+B2	<i>BRCA2</i> ⁻ + <i>hBRCA2</i>	Wt	VC8	[42]

REFERENCES:

- [1] A.R. Venkitaraman Cancer susceptibility and the functions of BRCA1 and BRCA2, *Cell* 108 (2002) 171-182.
- 5 [2] C. Lundin, K. Erixon, C. Arnaudeau, N. Schultz, D. Jenssen, M. Meuth and T. Helleday Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells, *Mol Cell Biol* 22 (2002) 5869-5878.
- [3] D. D'Amours, S. Desnoyers, I. D'Silva and G.G. Poirier Poly(ADP-
10 ribosyl)ation reactions in the regulation of nuclear functions, *Biochem J* 342 (1999) 249-268.
- [4] Z. Herceg and Z.Q. Wang Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death, *Mutat Res* 477 (2001) 97-110.
- 15 [5] T. Lindahl, M.S. Satoh, G.G. Poirier and A. Klungland Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks, *Trends Biochem Sci* 20 (1995) 405-411.
- [6] M.S. Satoh and T. Lindahl Role of poly(ADP-ribose) formation in DNA repair, *Nature* 356 (1992) 356-358.
- 20 [7] S. Shall and G. de Murcia Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?, *Mutat Res* 460 (2000) 1-15.
- [8] Z.Q. Wang, L. Stingl, C. Morrison, M. Jantsch, M. Los, K. Schulze-Osthoff and E.F. Wagner PARP is important for genomic stability but dispensable in apoptosis, *Genes Dev* 11 (1997) 2347-2358.
- 25 [9] C.M. Simbulan-Rosenthal, B.R. Haddad, D.S. Rosenthal, Z. Weaver, A. Coleman, R. Luo, H.M. Young, Z.Q. Wang, T. Ried and M.E. Smulson Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA, *Proc Natl Acad Sci U S A* 96 (1999) 13191-13196.
- 30 [10] J.M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, F.J. Oliver, M. Masson, A. Dierich, M. LeMeur, C. Walztinger, P. Chambon and G. de Murcia Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells, *Proc Natl Acad Sci U S A* 94 (1997) 7303-7307.

- [11] F. d'Adda di Fagagna, M.P. Hande, W.M. Tong, P.M. Lansdorp, Z.Q. Wang and S.P. Jackson Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability, *Nat Genet* 23 (1999) 76-80.
- 5 [12] E. Samper, F.A. Goytisolo, J. Menissier-de Murcia, E. Gonzalez-Suarez, J.C. Cigudosa, G. de Murcia and M.A. Blasco Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability, *J Cell Biol* 154 (2001) 49-60.
- 10 [13] C. Morrison, G.C. Smith, L. Stengl, S.P. Jackson, E.F. Wagner and Z.Q. Wang Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis, *Nat Genet* 17 (1997) 479-482.
- 15 [14] V. Schreiber, D. Hunting, C. Trucco, B. Gowans, D. Grunwald, G. De Murcia and J.M. De Murcia A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage, *Proc Natl Acad Sci U S A* 92 (1995) 4753-4757.
- [15] J.H. Kupper, M. Muller and A. Burkle Trans-dominant inhibition of poly(ADP-ribosyl)ation potentiates carcinogen induced gene amplification in SV40-transformed Chinese hamster cells, *Cancer Res* 56 (1996) 2715-2717.
- 20 [16] J. Magnusson and C. Ramel Inhibitor of poly(ADP-ribose)transferase potentiates the recombinogenic but not the mutagenic action of alkylating agents in somatic cells in vivo in *Drosophila melanogaster*, *Mutagenesis* 5 (1990) 511-514.
- 25 [17] A.S. Waldman and B.C. Waldman Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation), *Nucleic Acids Res* 19 (1991) 5943-5947.
- [18] A. Semionov, D. Cournoyer and T.Y. Chow Inhibition of poly(ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts, *Nucleic Acids Res* 27 (1999) 4526-4531.
- 30 [19] F. Dantzer, V. Schreiber, C. Niedergang, C. Trucco, E. Flatter, G. De La Rubia, J. Oliver, V. Rolli, J. Menissier-de Murcia and G. de Murcia Involvement of poly(ADP-ribose) polymerase in base excision repair, *Biochimie* 81 (1999) 69-75.

- [20] F. Dantzer, G. de La Rubia, J. Menissier-De Murcia, Z. Hostomsky, G. de Murcia and V. Schreiber Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1, *Biochemistry* 39 (2000) 7559-7569.
- [21] L. Tentori, I. Portarena and G. Graziani Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors, *Pharmacol Res* 45 (2002) 73-85.
- [22] T. Lindahl and R.D. Wood Quality control by DNA repair, *Science* 286 (1999) 1897-1905.
- [23] K.W. Caldecott DNA single-strand break repair and spinocerebellar ataxia, *Cell* 112 (2003) 7-10.
- [24] D. D'Amours and S.P. Jackson The Mre11 complex: at the crossroads of dna repair and checkpoint signalling, *Nat Rev Mol Cell Biol* 3 (2002) 317-327.
- [25] A.D. D'Andrea and M. Grompe The Fanconi anaemia/BRCA pathway, *Nat Rev Cancer* 3 (2003) 23-34.
- [26] S.P. Jackson Sensing and repairing DNA double-strand breaks, *Carcinogenesis* 23 (2002) 687-696.
- [27] R. Kanaar, J.H. Hoeijmakers and D.C. van Gent Molecular mechanisms of DNA double strand break repair, *Trends Cell Biol* 8 (1998) 483-489.
- [28] D.C. van Gent, J.H. Hoeijmakers and R. Kanaar Chromosomal stability and the DNA double-stranded break connection, *Nat Rev Genet* 2 (2001) 196-206.
- [29] S.L. Neuhausen and E.A. Ostrander Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2, *Genet Test* 1 (1997) 75-83.
- [30] G. Kuperstein, W.D. Foulkes, P. Ghadirian, J. Hakimi and S.A. Narod A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes, *Clin Genet* 57 (2000) 213-220.
- [31] A. Chiarugi Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited, *Trends Pharmacol Sci* 23 (2002) 122-129.
- [32] C.R. Calabrese, M.A. Batey, H.D. Thomas, B.W. Durkacz, L.Z. Wang, S. Kyle, D. Skalitzky, J. Li, C. Zhang, T. Boritzki, K. Maegley, A.H. Calvert, Z. Hostomsky, D.R. Newell and N.J. Curtin Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: Chemopotential and Pharmacological Studies, *Clin Cancer Res* 9 (2003) 2711-2718.
- [33] D. Ferraris, Y.S. Ko, T. Pahutski, R.P. Ficco, L. Serdyuk, C. Alemu, C. Bradford, T. Chiou, R. Hoover, S. Huang, S. Lautar, S. Liang, Q. Lin, M.X.

- Lu, M. Mooney, L. Morgan, Y. Qian, S. Tran, L.R. Williams, Q.Y. Wu, J. Zhang, Y. Zou and V. Kalish Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries, *J Med Chem* 46 (2003) 3138-3151.
- [34] K.J. Dillon, G.C. Smith and N.M. Martin A FlashPlate assay for the identification of PARP-1 inhibitors, *J Biomol Screen* 8 (2003) 347-352.
- [35] A.J. Pierce, R.D. Johnson, L.H. Thompson and M. Jasin XRCC3 promotes homology-directed repair of DNA damage in mammalian cells, *Genes Dev* 13 (1999) 2633-2638.
- [36] R.D. Johnson, N. Liu and M. Jasin Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination, *Nature* 401 (1999) 397-399.
- [37] G.M. Shah, D. Poirier, S. Desnoyers, S. Saint-Martin, J.C. Hoflack, P. Rong, M. ApSimon, J.B. Kirkland and G.G. Poirier Complete inhibition of poly(ADP-ribose) polymerase activity prevents the recovery of C3H10T1/2 cells from oxidative stress, *Biochim Biophys Acta* 1312 (1996) 1-7.
- [38] R.J. Griffin, S. Srinivasan, K. Bowman, A.H. Calvert, N.J. Curtin, D.R. Newell, L.C. Pemberton and B.T. Golding Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), *J Med Chem* 41 (1998) 5247-5256.
- [39] S. Boulton, L.C. Pemberton, J.K. Porteous, N.J. Curtin, R.J. Griffin, B.T. Golding and B.W. Durkacz Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors, *Br J Cancer* 72 (1995) 849-856.
- [40] C.S. Griffin, P.J. Simpson, C.R. Wilson and J. Thacker Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation, *Nat Cell Biol* 2 (2000) 757-761.
- [41] R.S. Tebbs, Y. Zhao, J.D. Tucker, J.B. Scheerer, M.J. Siciliano, M. Hwang, N. Liu, R.J. Legerski and L.H. Thompson Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene, *Proc Natl Acad Sci U S A* 92 (1995) 6354-6358.

- [42] M. Kraakman-van der Zwet, W.J. Overkamp, R.E. van Lange, J. Essers, A. van Duijn-Goedhart, I. Wiggers, S. Swaminathan, P.P. van Buul, A. Errami, R.T. Tan, N.G. Jaspers, S.K. Sharan, R. Kanaar and M.Z. Zdzienicka Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions, Mol Cell Biol 22 (2002) 669-679.
- [43] J. Nakamura, S. Asakura, S.D. Hester, G. de Murcia, K.W. Caldecott and J.A. Swenberg Quantitation of intracellular NAD(P)H can monitor an imbalance of DNA single strand break repair in base excision repair deficient cells in real time, Nucleic Acids Res 31 (2003) e104.
- [44] H. Halldorsson, D.A. Gray and S. Shall Poly (ADP-ribose) polymerase activity in nucleotide permeable cells, FEBS Lett 85 (1978) 349-352.
- [45] K. Grube, J.H. Kupper and A. Burkle Direct stimulation of poly(ADP ribose) polymerase in permeabilized cells by double-stranded DNA oligomers, Anal Biochem 193 (1991) 236-239.
- [46] C. Lundin, N. Schultz, C. Arnaudeau, A. Mohindra, L.T. Hansen and T. Helleday RAD51 is Involved in Repair of Damage Associated with DNA Replication in Mammalian Cells, J Mol Biol 328 (2003) 521-535.
- [47] Schreider et al., Journal of Biological Chemistry 277: 23028-23036 (2002).

SEQUENCE LISTING

<110> THE UNIVERSITY OF SHEFFIELD

<120> USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE
OF A MEDICAMENT FOR THE TREATMENT OF CANCER

<130> 60419-NP

<140> CA 2,533,423

<141> 2004-07-23

<150> PCT/GB2004/003235

<151> 2004-07-23

<150> UK 0317466.1

<151> 2003-07-25

<160> 9

<170> PatentIn version 3.2

<210> 1

<211> 21

<212> RNA

<213> Homo sapiens

<400> 1

aaaagccaug guggaguaug a

21

<210> 2

<211> 23

<212> RNA

<213> Homo sapiens

<400> 2

aagaccauc ucuccaguuc aac

23

<210> 3
 <211> 21
 <212> RNA
 <213> Homo sapiens

<400> 3
 aagaccaaca ucgagaacaa c 21

<210> 4
 <211> 5468
 <212> DNA
 <213> Homo sapiens

<400> 4
 cgcccgccca gccccggggg cagggaagc ctaaattacg gaattaccgc gagcaaggag 60
 cgcggaatcg gggagcgtcc ggagctagct ggatcctcta ggcaggatgg tgatgggaat 120
 ctttgcaaat tgtatcttct gtttgaaagt gaagtactta cctcagcagc agaagaaaaa 180
 gctacaaact gacattaagg aaaatggcgg aaagttttcc ttttcgttaa atcctcagtg 240
 cacacatata atcttagata atgctgatgt tctgagtcag taccaactga attctatcca 300
 aaagaaccac gttcatattg caaaccaga ttttatatgg aaatctatca gagaaaagag 360
 actcttggat gtaaagaatt atgatcctta taagcccctg gacatcacac cacctcctga 420
 tcagaaggcg agcagttctg aagtgaaaac agaaggctta tgcccggaaca gtgccacaga 480
 ggaggaagac actgtggaac tcaactgagtt tggatgcag aatgttgaaa ttcctcatct 540
 tcctcaagat tttgaagttg caaaatataa caccttggag aaagtgggaa tggagggagg 600
 ccaggaagct gtggtggtgg agcttcagtg ttgcgaggac tccagggact gtcctttcct 660
 gatatacctca cacttctctc tggatgatgg catggagact agaagacagt ttgctataaa 720
 gaaaacctct gaagatgcaa gtgaataact tgaaaattac attgaagaac tgaagaaaca 780
 aggatttcta ctaagagaac atttcacacc tgaagcaacc caattagcat ctgaacaatt 840
 gcaagcattg cttttggagg aagtcatgaa ttcaagcact ctgagccaag aggtgagcga 900
 tttagtagag atgatttggg cagaggccct gggccacctg gaacacatgc ttctcaagcc 960
 agtgaacagg attagcctca acgatgtgag caaggcagag gggattctcc ttctagtaaa 1020
 ggcagcactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagagtttta 1080
 cagactgata cctcaciaag gcacaatgcc caaagaagtg aacctgggac tattggctaa 1140
 gaaagcagac ctctgccagc taataagaga catggttaat gtctgtgaaa ctaatttgtc 1200
 caaacccaac ccaccatccc tggccaaata ccgagctttg aggtgcaaaa ttgagcatgt 1260
 tgaacagaat actgaagaat ttctcagggt tagaaaagag gttttgcaga atcatcacag 1320
 taagagccca gtggatgtct tgcagatatt tagagttggc agagtgaatg aaaccacaga 1380
 gtttttgagc aaacttggtg atgtgaggcc cttgttgcac ggttctcctg taaaaacat 1440

cgtgggaatc	ttgtgtcgag	ggttgctttt	acccaaagta	gtggaagatc	gtggtgtgca	1500
aagaacagac	gtcggaaacc	ttggaagtgg	gatttatattc	agtgattcgc	tcagtacaag	1560
tatcaagtac	tcacacccgg	gagagacaga	tggcaccaga	ctcctgctca	tttgtgacgt	1620
agccctcgga	aagtgtatgg	acttacatga	gaaggacttt	tccttaactg	aagcaccacc	1680
aggctacgac	agtgtgcatg	gagtttcaca	aacagcctct	gtcaccacag	actttgagga	1740
tgatgaattt	gttgtctata	aaaccaatca	ggttaaaatg	aaatatatta	ttaaattttc	1800
catgcctgga	gatcagataa	aggactttca	tcctagtgat	catactgaat	tagaggaata	1860
cagacctgag	ttttcaaatt	tttcaaaggt	tgaagattac	cagttaccag	atgccaaaac	1920
ttccagcagc	accaaggccg	gcctccagga	tgcttctggg	aacttggttc	ctctggagga	1980
tgccacatc	aaagggagaa	tcatagacac	tgtagcccag	gtcattgttt	ttcagacata	2040
cacaaataaa	agtcacgtgc	ccattgaggc	aaaatatatc	tttcctttgg	atgacaaggc	2100
cgctgtgtgt	ggcttcgaag	ccttcatcaa	tgggaagcac	atagttggag	agattaaaga	2160
gaaggaagaa	gccagcaag	agtacctaga	agccgtgacc	cagggccatg	gcgcttacct	2220
gatgagtcag	gatgctccgg	acgtttttac	tgtaagtgtt	ggaaacttac	cccctaaggc	2280
taaggttctt	ataaaaatta	cctacatcac	agaactcagc	atcctgggca	ctgttggtgt	2340
ctttttcatg	ccgccaccg	tagcaccctg	gcaacaggac	aaggctttga	atgaaaacct	2400
tcaggataca	gtagagaaga	tttgtataaa	agaaatagga	acaaagcaaa	gcttctcttt	2460
gactatgtct	attgagatgc	cgtacgtgat	tgaattcatt	ttcagtgata	ctcatgaact	2520
gaaacaaaag	cgcacagact	gcaaagctgt	cattagcacc	atggaaggca	gctccttaga	2580
cagcagtgga	ttttctctcc	acatcggttt	gtctgctgcc	tatctcccaa	gaatgtgggt	2640
tgaaaaacat	ccagaaaaag	aaagcgaggc	ttgcatgctt	gtctttcaac	ccgatctcga	2700
tgctcgacctc	cctgacctag	ccaatgagag	cgaagtgatt	atttgtcttg	actgctccag	2760
ttccatggag	ggtgtgacat	tcttgcaagc	caaggaaatc	gccttgcatg	cgctgtcctt	2820
ggtgggtgag	aagcagaaaag	taaatattat	ccagttcggc	acaggttaca	aggagctatt	2880
ttcgtatcct	aagcatatca	caagcaatac	cgcggcagca	gagttcatca	tgtctgccac	2940
acctaccatg	gggaacacag	acttctggaa	aacactccga	tatcttagct	tattgtaccc	3000
tgctcgaggg	tcacggaaca	tcctcctggg	gtctgatggg	cacctccagg	atgagagcct	3060
gacattacag	ctcgtgaaga	ggagccgccc	gcacaccagg	ttattcgcct	gcggtatcgg	3120
ttctacagca	aatcgtcacg	tcttaaggat	tttgtcccag	tgtgggtgccg	gagtatttga	3180
atattttaat	gcaaaatcca	agcatagttg	gagaaaacag	atagaagacc	aatgaccag	3240
gctatgttct	ccgagttgcc	actctgtctc	cgtcaaatgg	cagcaactca	atccagatgc	3300
gcccagaggcc	ctgcaggccc	cagcccagggt	gccatccttg	tttcgcaatg	atcgactcct	3360
tgtctatgga	ttcattcctc	actgcacaca	ggcaactctg	tgtgcactaa	ttcaagagaa	3420
agaattttgt	acaatggtgt	cgactactga	gcttcagaag	acaactggaa	ctatgatcca	3480
caagctggca	gcccagagctc	taatcagaga	ttatgaagat	ggcattcttc	acgaaaatga	3540
aaccagtcac	gagatgaaaa	aacaaacctt	gaaatctctg	attattaaac	tcagtaaaga	3600
aaactctctc	ataacacaat	ttacaagctt	tgtggcagtt	gagaaaaggg	atgagaatga	3660
gtcacctttt	cctgatattc	caaaagtttc	tgaacttatt	gccaaagaag	atgtagactt	3720
cctgccctac	atgagctggc	agggggaacc	ccaagaagcc	gtcaggaacc	agtctctttt	3780

agcatcctct	gagtggccag	aattacgttt	atccaaacga	aaacatagga	aaattccatt	3840
ttccaaaaga	aaaatggaat	tatctcagcc	agaagtttct	gaagattttg	aagaggatgc	3900
cttaggtgta	ctaccagctt	tcacatcaaa	tttggaacgt	ggacgtgtgg	aaaagctatt	3960
ggattttaagt	tggacagagt	catgtaaacc	aacagcaact	gaaccactat	ttaagaaagt	4020
cagtccatgg	gaaacatcta	cttctagctt	ttttcctatt	ttggctccgg	ccgttggttc	4080
ctatcttacc	cogactaccc	gcgctcacag	tcctgcttcc	ttgtcttttg	cctcatatcg	4140
tcaggtagct	agtttcgggt	cagctgctcc	tcccagacag	tttgatgcat	ctcaattcag	4200
ccaaggccct	gtgcctggca	cttgtgctga	ctggatccca	cagtcggcgt	cttgtcccac	4260
aggacctccc	cagaacccac	cttctgcacc	ctattgtggc	attgtttttt	cagggagctc	4320
attaagctct	gcacagtctg	ctccactgca	acatcctgga	ggctttacta	ccaggccttc	4380
tgctggcacc	ttccctgagc	tggattctcc	ccagcttcat	ttctctcttc	ctacagaccc	4440
tgatcccac	agaggttttg	ggtcttatca	tccctctgct	tactctcctt	ttcattttca	4500
accttccgca	gcctctttga	ctgccaacct	taggctgcca	atggcctctg	ctttacctga	4560
ggctctttgc	agtcagtccc	ggactacccc	agtagatctc	tgtcttctag	aagaatcagt	4620
aggcagtctc	gaaggaagtc	gatgtcctgt	ctttgctttt	caaagttctg	acacagaaag	4680
tgatgagcta	tcagaagtac	ttcaagacag	ctgcttttta	caaataaaaat	gtgatacaaa	4740
agatgacagt	atcccgtgct	ttctggaagt	aaaagaagag	gatgaaatag	tgtgcacaca	4800
acactggcag	gatgctgtgc	cttggacaga	actcctcagt	ctacagacag	aggatggctt	4860
ctggaaactt	acaccagaac	tgggacttat	attaaatctt	aatacaaatg	gtttgcacag	4920
ctttcttaaa	caaaaaggca	ttcaatctct	aggtgtaaaa	ggaagagaat	gtctcctgga	4980
cctaattgcc	acaatgctgg	tactacagtt	tattcgcacc	aggttggaaa	aagagggaat	5040
agtgttcaaa	tcactgatga	aatggatga	cccttctatt	tccaggaata	ttccctgggc	5100
ttttgaggca	ataaagcaag	caagtgaatg	ggtaagaaga	actgaaggac	agtacccatc	5160
tatctgcccc	cggcttgaac	tggggaacga	ctgggactct	gccaccaagc	agttgctggg	5220
actccagccc	ataagcactg	tgtccctctc	tcatagagtc	ctccattaca	gtcaaggcta	5280
agtcaaatga	aactgaatth	taaacttttt	gcatgcttct	atgtagaaaa	taatcaaatg	5340
ataatagata	cttataatga	aacttcatta	aggtttcatt	cagtgtagca	attactgtct	5400
ttaaaaatta	agtggaagaa	gaattacttt	aatcaactaa	caagcaataa	taaaatgaaa	5460
cttaaaat						5468

<210> 5

<211> 1910

<212> DNA

<213> Homo sapiens

<400> 5

ctagaattca	gcgcccgctg	aattctaggc	ggcgcgggcg	cgacggagca	ccggcgggcg	60
cagggcgaga	gcattaaatg	aaagcaaaag	agttaataat	ggcaacacgg	ctccagaaga	120

```

ctcttcccct gccaaagaaa ctcttagatg ccagagacag gagtcgaaaa agatgcctgt 180
ggctggagga aaagctaata aggacaggac agaagacaag caagatggta tgccaggaag 240
gtcatgggcc agcaaaaggg tctctgaatc tgtgaaggcc ttgctgttaa agggcaaagc 300
tcctgtggac ccagagtgtg cagccaaggc ggggaaggct catgtgtatt gtgaaggaaa 360
tgatgtctat gatgtcatgc taaatcagac caatctccag ttcaacaaca acaagtacta 420
tctgattcag ctattagaag atgatgccca gaggaacttc agtgtttgga tgagatgggg 480
ccgagttggg aaaatgggac agcacagcct ggtggcttgt tcaggcaatc tcaacaaggc 540
caaggaaatc tttcagaaga aattccttga caaaacgaaa aacaattggg aagatcgaga 600
aaagtttgag aaggtgcctg gaaaatatga tatgctacag atggactatg ccaccaatac 660
tcaggatgaa gaggaacaaa aaaaagagga atctcttaaa tctcccttga agccagagtc 720
acagctagat cttcgggtac aggagttaat aaagttgatc tgtaatgttc aggccatgga 780
agaaatgatg atggaaatga agtataatac caagaaagcc ccacttggga agctgacagt 840
ggcacaaatc aaggcagggt accagtctct taagaagatt gaggattgta ttcgggctgg 900
ccagcatgga cgagctctca tggaagcatg caatgaattc tacaccagga ttccgcatga 960
ctttggactc cgtactcctc cactaatccg gacacagaag gaactgtcag aaaaaataca 1020
attactagag gctttgggag acattgaaat tgctattaag ctggtgaaaa cagagctaca 1080
aagcccagaa caccattgg accaacacta tagaaaccta catttgtcct tgcgccccct 1140
tgaccatgaa agttacgagt tcaaagtgat ttcccagtac ctacaatcta cccatgctcc 1200
cacacacagc gactatacca tgaccttgct ggattttgtt gaagtggaga aggatgggtg 1260
gaaagaagcc ttcagagagg accttcataa caggatgctt ctatggcatg gttccaggat 1320
gagtaactgg gtgggaatct tgagccatgg gcttcgaatt gccaccctg aagctcccat 1380
cacaggttac atgtttggga aaggaatcta ctttgctgac atgtcttcca agagtgccaa 1440
ttactgcttt gcctctcgcc taaagaatac aggactgctg ctcttatcag aggtagctct 1500
aggtcagtgt aatgaactac tagaggccaa tcctaaggcc gaaggattgc ttcaaggtaa 1560
acatagcacc aaggggctgg gcaagatggc tcccagttct gccacttcg tcacctgaa 1620
tgaggagtaca gtgccattag gaccagcaag tgacacagga attctgaatc cagatgggta 1680
tacctcaac tacaatgaat atattgtata taacccaac caggtcgta tgcggtacct 1740
tttaaagggt cagtttaatt tccttcagct gtggtgaatg ttgatcttaa ataaaccaga 1800
gatctgatct tcaagcaaga aaataagcag tgttgtactt gtgaattttg tgatatttta 1860
tgtaataaaa actgtacagg tctaaaaaaa aaaaaaaaaa aaaaaaaaaa 1910

```

<210> 6

<211> 2263

<212> DNA

<213> Homo sapiens

<400> 6

```

tgggactggg cgctgactc ggctgcccc agcctctgct tcacccact ggtggccaaa 60

```

tagccgatgt	ctaatacccc	acacaagctc	atccccggcc	tctgggattg	ttgggaattc	120
tctccctaata	tcacgcctga	ggctcatgga	gagttgctag	acctgggact	gccctgggag	180
gcgcacacaa	ccaggccggg	tggcagccag	gacctctccc	atgtccctgc	ttttcttggc	240
catggctcca	aagccgaagc	cctgggtaca	gactgagggc	cctgagaaga	agaagggccg	300
gcaggcagga	agggaggagg	accccttccg	ctccaccgct	gaggccctca	aggccatacc	360
cgcagagaag	cgcataatcc	gcgtggatcc	aacatgtcca	ctcagcagca	accccgggac	420
ccaggtgtat	gaggactaca	actgcaccct	gaaccagacc	aacatcgaga	acaacaacaa	480
caagttctac	atcatccagc	tgctccaaga	cagcaaccgc	ttcttcacct	gctggaaccg	540
ctggggccgt	gtgggagagg	tcggccagtc	aaagatcaac	cacttcacaa	ggctagaaga	600
tgcaaagaag	gacttttgaga	agaaatttcg	ggaaaagacc	aagaacaact	gggcagagcg	660
ggaccacttt	gtgtctcacc	cgggcaagta	cacacttata	gaagtacagg	cagaggatga	720
ggcccaggaa	gctgtggtga	aggtggacag	aggcccagtg	aggactgtga	ctaagcgggt	780
gcagccctgc	tccttggaac	cagccacgca	gaagctcctc	actaacatct	tcagcaagga	840
gatgttcaag	aacaccatgg	ccctcatgga	cctggatgtg	aagaagatgc	ccctgggaaa	900
gctgagcaag	caacagattg	cacgggggtt	cgaggccttg	gaggcgctgg	aggaggccct	960
gaaaggcccc	acggatgggt	gccaaagcct	ggaggagctg	tcctcacact	tttacaccgt	1020
catcccgcac	aacttcggcc	acagccagcc	cccgccctac	aattccccctg	agcttctgca	1080
ggccaagaag	gacatgctgc	tggtgctggc	ggacatcgag	ctggcccagg	ccctgcaggc	1140
agtctctgag	caggagaaga	cgggtggagga	ggtgccacac	cccctggacc	gagactacca	1200
gcttctcaag	tgccagctgc	agctgctaga	ctctggagca	cctgagtaca	aggtgataca	1260
gacctactta	gaacagactg	gcagcaacca	caggtgccct	acacttcaac	acatctggaa	1320
agtaaaccac	gaaggggagg	aagacagatt	ccaggcccac	tccaaactgg	gtaatcggaa	1380
gctgctgtgg	catggcacca	acatggccgt	ggtggccgcc	atcctcacta	gtgggctccg	1440
catcatgcc	cattctgggt	ggcgtgttgg	caagggcctc	tactttgcct	cagagaacag	1500
caagtcagct	ggatatgtta	ttggcatgaa	gtgtggggcc	caccatgtcg	gctacatgtt	1560
cctgggtgag	gtggccctgg	gcagagagca	ccatatcaac	acggacaacc	ccagcttgaa	1620
gagccacact	cctggcttcg	acagtgtcat	tgcccagagg	cacaccgagc	ctgatccgac	1680
ccaggacact	gagttggagc	tggatggcca	gcaagtgggt	gtgccccagg	gccagcctgt	1740
gccctgcca	gagttcagca	gctccacatt	ctcccagagc	gagtacctca	tctaccagga	1800
gagccagtgt	cgcctgcgct	acctgctgga	ggtccacctc	tgagtgcccg	ccctgtcccc	1860
cggggctcctg	caaggctgga	ctgtgatctt	caatcatcct	gcccattctct	ggtaccctta	1920
tatcactcct	ttttttcaag	aatacaatac	gttggtgtta	actatagtca	ccatgctgta	1980
caagatecct	gaacttatgc	ctcctaactg	aaattttgta	ttctttgaca	catctgcca	2040
gtccctctcc	tcccagccca	tggtaaccag	catttgactc	tttacttgta	taagggcagc	2100
ttttataggt	tccacatgta	agtgagatca	tgcagtgttt	gtctttctgt	gcctggctta	2160
tttcactcag	cataatgtgc	accgggttca	cccatgtttt	cataaatgac	aagatttcct	2220
cctttaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaa		2263

<210> 7
 <211> 4491
 <212> DNA
 <213> Homo sapiens

<400> 7

cgaagatggc	ggcgtcgcgt	cgctctcagc	atcatcacca	ccatcatcaa	caacagctcc	60
agcccgcccc	aggggcttca	gcgccgcgcg	cgccacctcc	tccccactc	agccctggcc	120
tgcccccggg	gaccacccca	gcctctccca	cggccagcgg	cctggccccc	ttcgctccc	180
cgcggcacgg	cctagcgcgt	ccggaggggg	atggcagtcg	ggatccgccc	gacaggcccc	240
gacccccgga	cccggttgac	ggtaccagct	gttgcagtac	caccagcaca	atctgtaccg	300
tcgccgcgcg	tcccggtggc	ccagcgggtt	ctacttcctc	tgccgctggg	gtcgtctcca	360
accagccgg	cagtggcagt	aacaattcac	cgtcgtcctc	ttcttccccg	acttcttctt	420
catcttctc	tccatcctcc	cctggatcga	gcttggcggg	gagccccgag	gcggccggag	480
ttagcagcac	agcaccactg	gggcctgggg	cagcaggacc	tgggacaggg	gtcccagcag	540
tgagcggggc	cctacgggaa	ctgctggagg	cctgtcgcaa	tggggacgtg	tcccgggtaa	600
agaggctgg	ggacgcggca	aacgtaaagt	caaaggacat	ggccggccgg	aagtcttctc	660
ccctgcactt	cgtgcaggt	tttggaagga	aggatgttgt	agaacactta	ctacagatgg	720
gtgctaagt	ccacgctcgt	gatgatggag	gtctcatccc	gcttcataat	gcctgttctt	780
ttggccatgc	tgaggttgtg	agtctgttat	tgtgccaaag	agctgatcca	aatgccaggg	840
ataactggaa	ctatacacct	ctgcatgaag	ctgctattaa	agggaagatc	gatgtgtgca	900
ttgtgctgct	gcagcacgga	gctgacccaa	acattcgga	caatgatggg	aaatcagccc	960
tggacctggc	agatccttca	gcaaaagctg	tccttacagg	tgaatacaag	aaagacgaac	1020
tcctagaagc	tgctaggagt	ggtaatgaag	aaaaactaat	ggctttactg	actcctctaa	1080
atgtgaattg	ccatgcaagt	gatgggcgaa	agtcgactcc	tttacatcta	gcagcgggct	1140
acaacagagt	tcgaatagtt	cagcttcttc	ttcagcatgg	tgctgatgtt	catgcaaaag	1200
acaaagggtg	acttgtgcct	cttcataatg	catgttcata	tggacattat	gaagtcacag	1260
aactgctact	aaagcatgga	gcttgtgtta	atgccatgga	tctctggcag	tttactccac	1320
tgcacgaggc	tgttccaag	aaccgtgtag	aagtctgctc	tttgttactt	agccatggcg	1380
ctgatcctac	gttagtcaac	tgccatggca	aaagtgtgtg	ggatatggct	ccaactccgg	1440
agcttaggga	gagattgact	tatgaattta	aaggctcttc	tttactacaa	gcagccagag	1500
aagcagactt	agctaaagtt	aaaaaaacac	tcgctctgga	aatcattaat	ttcaaacaac	1560
cgcagtctca	tgaacacagc	ctgcactgtg	ctgtggcctc	tctgcacccc	aaacgtaaac	1620
aagtgcagca	attgttactt	agaaaaggag	caaatgttaa	tgaaaaaaat	aaagatttca	1680
tgactcccct	gcatgttgca	gccgaaagag	cccataatga	tgtcatggaa	gttctgcata	1740
agcatggcgc	caagatgaat	gcactggaca	cccttgggtc	gactgctttg	catagagccg	1800
ccctagcagg	ccacctgcag	acctgccgcc	tcctgctgag	ttacggctct	gacccctcca	1860
tcctctcctt	acaaggcttc	acagcagcac	agatgggcaa	tgaagcagtg	cagcagattc	1920
tgagtgtgag	ttacggctct	gacccctcca	tcctctcctt	acaaggcttc	acagcagcac	1980

agatgggcaa	tgaagcagtg	cagcagattc	tgagtgggtca	ttcgtagata	gtgatcattc	2040
tacttcagcc	ttaatgggtga	tcttgagacg	ggaagattta	gaaggaaatc	tatccagcat	2100
gtcttcactg	tcaacatgaa	gagtacacct	atacgtactt	ctgatgttga	ttatcgactc	2160
ttagaggcat	ctaaagctgg	agacttggaa	actgtgaagc	aactttgcag	ctctcaaaat	2220
gtgaattgta	gagacttaga	gggccggcat	tccacgcctt	tacacttcgc	agcaggctac	2280
aacagagtac	acctatacgt	acttctgatg	ttgattatcg	actcttagag	gcatctaaag	2340
ctggagactt	ggaaactgtg	aagcaacttt	gcagctctca	aaatgtgaat	tgtagagact	2400
tagagggccg	gcattccacg	cccttacact	tcgcagcagg	ctacaaccgc	gtgtctgttg	2460
tagagtacct	gctacaccac	ggtgccgatg	tccatgccaa	agacaagggt	ggcttggtgc	2520
cccttcataa	tgccctgttca	tatggacact	atgaggtggc	tgagctttta	gtaaggcatg	2580
gggcttctgt	caatgtggcg	gacttatgga	aattttacccc	tctccatgaa	gcagcagcta	2640
aaggaaagta	tgaaatctgc	aagctccttt	taaaacatgg	agcagatcca	actaaaaaga	2700
acagagatgg	aaatacacct	ttggatttgg	taaaggaagg	agacacagat	attcaggact	2760
tactgaaagg	ggatgctgct	ttggttgatg	ctgccaaaga	gggctgcctg	gcaagagtgc	2820
agaagctctg	taccccagag	aatatcaact	gcagagacac	ccagggcaga	aattcaaccc	2880
ctctgcacct	ggcagcaggc	tataataacc	tggaagtagc	tgaatatctt	ctagagcatg	2940
gagctgatgt	taatgcccag	gacaaggggtg	gtttaattcc	tcttcataat	gcggcatctt	3000
atgggcatgt	tgacatagcg	gctttattga	taaaatacaa	cacgtgtgta	aatgcaacag	3060
ataagtgggc	gtttactccc	ctccatgaag	cagcccagaa	aggaaggacg	cagctgtgcg	3120
ccctcctcct	agcgcatggt	gcagacccca	ccatgaagaa	ccaggaaggc	cagacgcctc	3180
tggatctggc	aacagctgac	gatatacagag	ctttgctgat	agatgccatg	ccccagagg	3240
ccttacctac	ctgtttttaa	cctcaggcta	ctgtagtgag	tgccctctctg	atctcaccag	3300
catccacccc	ctcctgcctc	tcggctgcca	gcagcataga	caacctcact	ggccctttag	3360
cagagttggc	cgtaggagga	gcctccaatg	caggggatgg	cgccgcggga	acagaaagga	3420
aggaaggaga	agttgctggt	cttgacatga	atatcagcca	atttctaaaa	agccttggcc	3480
ttgaacacct	tcgggatata	tttgaaacag	aacagattac	actagatgtg	ttggctgata	3540
tgggtcatga	agagttgaaa	gaaataggca	tcaatgcata	tgggcaccgc	cacaaattaa	3600
tcaaaggagt	agaaagactc	ttaggtggac	aacaaggcac	caatccttat	ttgacttttc	3660
actgtgttaa	tcagggaacg	attttgctgg	atcttgctcc	agaagataaa	gaatatcagt	3720
cagtggaaga	agagatgcaa	agtactattc	gagaacacag	agatggtggt	aatgctggcg	3780
gcatcttcaa	cagatacaat	gtcattcgaa	ttcaaaaagt	tgtcaacaag	aagttgaggg	3840
agcggttctg	ccaccgacag	aaggaagtgt	ctgaggagaa	tcacaaccat	cacaatgagc	3900
gcatgttggt	tcatggttct	cctttcatta	atgccattat	tcataaaggg	tttgatgagc	3960
gacatgcata	cataggagga	atgtttgggg	ccgggattta	ttttgctgaa	aactcctcaa	4020
aaagcaacca	atatgtttat	ggaattggag	gaggaacagg	ctgccctaca	cacaaggaca	4080
ggtcatgcta	tatatgtcac	agacaaatgc	tcttctgtag	agtgaccctt	gggaaatcct	4140
ttctgcagtt	tagcaccatg	aaaatggccc	acgcgcctcc	agggcaccac	tcagtcattg	4200
gtagaccgag	cgtcaatggg	ctggcatatg	ctgaatatgt	catctacaga	ggagaacagg	4260
cataccacga	gtatcttata	acttaccaga	tcatgaagcc	agaagccctt	tcccagaccg	4320

caacagccgc	agagcagaag	acctagtga	tgcctgctgg	tgaaggccag	atcagatttc	4380
aacctgggac	tggattacag	aggattgttt	ctaataacaa	catcaatatt	ctagaagtcc	4440
ctgacagcct	agaaataagc	tgtttgtctt	ctataaagca	ttgctatagt	g	4491

<210> 8

<211> 6189

<212> DNA

<213> Homo sapiens

<400> 8

cgcgccgcct	cgctagccga	aacctgccc	gccggtgcc	ggccactgcg	cacgcgcggg	60
acgacgtcac	gtgcgctccc	ggggctggac	ggagctggca	ggaggggcct	tgccagcttc	120
cgccgcgcgc	tcgtttcagg	acccggacgg	cggattcgcg	ctgcctccgc	cgccgcgggg	180
cagccggggg	gcaggagacc	cagcgagggg	cgcgctggg	cgcggccatg	ggactgcgcc	240
ggatccggtg	acagcaggg	gccaagcggc	ccgggccctg	agcgcgctct	ctccgggggg	300
cctcgccctc	ctgctcgcg	ggccggggct	cctgctccgg	ttgctggcgc	tgcttgctggc	360
tgtggcgggc	gccaggatca	tgtcgggtcg	ccgctgcgcc	ggcgggggag	cggcctgcgc	420
gagcgccgcg	gccgaggccg	tggagccggc	cgcccagag	ctgttcgagg	cgtgccgcaa	480
cggggacgtg	gaacgagtca	agaggctggt	gacgcctgag	aaggtgaaca	gccgcgacac	540
ggcgggcagg	aaatccaccc	cgctgcactt	cgcgcaggt	tttgggcgga	aagacgtagt	600
tgaatatattg	cttcagaatg	gtgcaaattg	ccaagcacgt	gatgatgggg	gccttattcc	660
tcttcataat	gcatgctctt	ttggtcatgc	tgaagtagtc	aatctccttt	tgcgacatgg	720
tgcagacccc	aatgctcgag	ataattggaa	ttatactcct	ctccatgaag	ctgcaattaa	780
aggaaagatt	gatgtttgca	ttgtgctggt	acagcatgga	gctgagccaa	ccatccgaaa	840
tacagatgga	aggacagcat	tggatttagc	agatccatct	gccaaagcag	tgcttactgg	900
tgaatataag	aaagatgaac	tcttagaaag	tgccaggagt	ggcaatgaag	aaaaaatgat	960
ggctctactc	acaccattaa	atgtcaactg	ccacgcaagt	gatggcagaa	agtcaactcc	1020
attacatttg	gcagcaggat	ataacagagt	aaagattgta	cagctgttac	tgcaacatgg	1080
agctgatgtc	catgctaaag	ataaagggtg	tctggtacca	ttacacaatg	cctgttctta	1140
tggtcattat	gaagtaactg	aacttttggg	caagcatggg	gcctgtgtaa	atgcaatgga	1200
cttgtggcaa	ttcactcctc	ttcatgaggc	agcttctaag	aacagggttg	aagtatgttc	1260
tcttctctta	agttatgggt	cagacccaac	actgctcaat	tgtcacaata	aaagtgctat	1320
agacttgggt	cccacaccac	agttaaaaga	aagattagca	tatgaattta	aaggccactc	1380
gttgctgcaa	gctgcacgag	aagctgatgt	tactcgaatc	aaaaaacatc	tctctctgga	1440
aatgggtgaat	ttcaagcatc	ctcaaacaca	tgaacagca	ttgcattgtg	ctgctgcata	1500
tccatatccc	aaaagaaagc	aaatatgtga	actgttgcta	agaaaaggag	caaacatcaa	1560
tgaaaagact	aaagaattct	tgactcctct	gcacgtggca	tctgagaaag	ctcataatga	1620
tgttgttgaa	gtagtggtga	aacatgaagc	aaagggtta	gctctggata	atcttggtca	1680

gacttctcta	cacagagctg	catattgtgg	tcatctacaa	acctgccgcc	tactcctgag	1740
ctatgggtgt	gacctaaca	ttatatccct	tcagggcttt	actgctttac	agatgggaaa	1800
tgaaaatgta	cagcaactcc	tccaagaggg	tatctcatta	ggtaattcag	aggcagacag	1860
acaattgctg	gaagctgcaa	aggctggaga	tgtcgaaact	gtaaaaaac	tgtgtactgt	1920
tcagagtgtc	aactgcagag	acattgaagg	gcgtcagtct	acaccacttc	attttgcagc	1980
tgggtataac	agagtgtccg	tgggtggaata	tctgctacag	catggagctg	atgtgcatgc	2040
taaagataaa	ggaggccttg	tacctttgca	caatgcatgt	tcttatggac	attatgaagt	2100
tgcagaactt	cttgttaaac	atggagcagt	agttaatgta	gctgatttat	ggaaatttac	2160
acctttacat	gaagcagcag	caaaaggaaa	atatgaaatt	tgcaaacctc	tgctccagca	2220
tgggtgcagac	cctacaaaaa	aaaacagggg	tggaaatact	cctttggatc	ttgttaaaga	2280
tggagataca	gatattcaag	atctgcttag	gggagatgca	gctttgctag	atgctgccaa	2340
gaagggttgt	ttagccagag	tgaagaagtt	gtcttctcct	gataatgtaa	attgccgcga	2400
taccaagggc	agacattcaa	cacctttaca	tttagcagct	ggttataata	atttagaagt	2460
tgcagagtat	ttgttacaac	acggagctga	tgtgaatgcc	caagacaaag	gaggacttat	2520
tcctttacat	aatgcagcat	cttacgggca	tgtagatgta	gcagctctac	taataaagta	2580
taatgcatgt	gtcaatgcca	cggacaaatg	ggctttcaca	cctttgcacg	aagcagccca	2640
aaagggacga	acacagcttt	gtgctttggt	gctagcccat	ggagctgacc	cgactcttaa	2700
aatcaggaa	ggacaaacac	cttttagattt	agtttcagca	gatgatgtca	gcgctcttct	2760
gacagcagcc	atgcccccat	ctgctctgcc	ctcttgttac	aagcctcaag	tgctcaatgg	2820
tgtgagaagc	ccaggagcca	ctgcagatgc	tctctcttca	gggccatcta	gccccatcaag	2880
cctttctgca	gccagcagtc	ttgacaactt	atctgggagt	ttttcagaac	tgtcttcagt	2940
agttagttca	agtggaacag	aggggtgcttc	cagtttggag	aaaaaggagg	ttccaggagt	3000
agatttttagc	ataactcaat	tcgtaaggaa	tcttggactt	gagcacctaa	tggatatatt	3060
tgagagagaa	cagatcactt	tggatgtatt	agttgagatg	gggcacaagg	agctgaagga	3120
gattggaatc	aatgcttatg	gacataggca	caaactaatt	aaaggagtcg	agagacttat	3180
ctccggacaa	caaggtctta	acccatatatt	aactttgaac	acctctggta	gtggaacaat	3240
tcttatagat	ctgtctcctg	atgataaaga	gtttcagtct	gtggaggaag	agatgcaaag	3300
tacagttcga	gagcacagag	atggagggtca	tgcagggtga	atcttcaaca	gatacaatat	3360
tctcaagatt	cagaagggtt	gtaacaagaa	actatgggaa	agatacactc	accggagaaa	3420
agaagtttct	gaagaaaacc	acaaccatgc	caatgaacga	atgctatttc	atgggtctcc	3480
ttttgtgaat	gcaattatcc	acaaaggctt	tgatgaaagg	catgcgtaca	taggtggtat	3540
gtttggagct	ggcatttatt	ttgctgaaaa	ctcttccaaa	agcaatcaat	atgtatatgg	3600
aattggagga	ggtactgggt	gtccagttca	caaagacaga	tcttgttaca	tttgccacag	3660
gcagctgctc	ttttgccggg	taaccttggg	aaagtctttc	ctgcagttca	gtgcaatgaa	3720
aatggcacat	tctcctccag	gtcatcactc	agtcactggg	aggcccagtg	taaatggcct	3780
agcattagct	gaatatgtta	tttacagagg	agaacaggct	tatcctgagt	atttaattac	3840
ttaccagatt	atgaggcctg	aagggtatgg	cgatggataa	atagttatatt	taagaaacta	3900
attccactga	acctaaaatc	atcaaagcag	cagtggcctc	tacgtttttac	tcctttgctg	3960
aaaaaaaaatc	atcttgccca	caggcctgtg	gcaaaaggat	aaaaatgtga	acgaagttta	4020

acattctgac	ttgataaagc	tttaataatg	tacagtgttt	tctaaatatt	tcctgttttt	4080
tcagcacttt	aacagatgcc	attccagggt	aaactgggtt	gtctgtacta	aattataaac	4140
agagttaact	tgaacctttt	atatgttatg	cattgattct	aacaaactgt	aatgccctca	4200
acagaactaa	ttttactaat	acaatactgt	gttcttttaa	acacagcatt	tacactgaat	4260
acaatttcat	ttgtaaaaact	gtaaataaga	gcttttgtac	tagcccagta	tttattttaca	4320
ttgctttgta	atataaatct	gtttttagaac	tgcagcggtt	tacaaaattt	tttcatatgt	4380
attgtttcatc	tatacttcat	cttacatcgt	catgattgag	tgatctttac	atttgattcc	4440
agaggctatg	ttcagttggt	agttgggaaa	gattgagtta	tcagatttaa	tttgccgatg	4500
ggagccttta	tctgtcatta	gaaatctttc	tcatttaaga	acttatgaat	atgctgaaga	4560
tttaatttgt	gatacctttg	tatgtatgag	acacattcca	aagagctcta	actatgatag	4620
gtcctgatta	ctaaagaagc	ttctttactg	gcctcaattt	ctagctttca	tgttggaaaa	4680
ttttctgcag	tccttctgtg	aaaattagag	caaagtgtct	ctgtttttta	gagaaactaa	4740
atcttgctgt	tgaacaatta	ttgtgttctt	ttcatggaac	ataagtagga	tgtaaacatt	4800
tccagggtgg	gaagggtaat	cctaaatcat	ttcccaatct	attctaatta	ccttaaactct	4860
aaaggggaaa	aaaaaaatca	caaacaggac	tgggtagttt	tttatcctaa	gtatatTTTT	4920
tcctgttctt	tttacttggg	tttattgctg	tatttatagc	caatctatac	atcatgggta	4980
aacttaaccc	agaactataa	aatgtagttg	tttcagtcct	cttcaggcct	cctgaatggg	5040
caagtgcagt	gaaacaggtg	cttctgtctc	ctgggttttc	tctccatgat	gttatgccca	5100
attggaaata	tgctgtcagt	ttgtgcacca	tatgggtgacc	acgcctgtgc	tcagtttggc	5160
agctatagaa	ggaaatgctg	tcccataaaa	tgccatccct	atttctaata	taacactctt	5220
ttccaggaag	catgcttaag	catcttggtt	cagagacata	catccattat	ggcttggcaa	5280
tctcttttat	ttgttgactc	tagctccctt	caaagtcgag	gaaagatctt	tactcactta	5340
atgaggacat	tcccatcac	tgtctgtacc	agttcacctt	tattttacgt	tttattcagt	5400
ctgtaaatta	actggccctt	tgcagtaact	tgtacataaa	gtgctagaaa	atcatgttcc	5460
ttgtcctgag	taagagttaa	tcagagtaag	tgcatttctg	gagttgtttc	tgtgatgtaa	5520
attatgatca	ttatttaaga	agtcaaatcc	tgatcttgaa	gtgcttttta	tacagctctc	5580
taataattac	aatatccga	aagtcatttc	ttggaacaca	agtggagtat	gccaaatttt	5640
atatgaattt	ttcagattat	ctaagcttcc	aggttttata	attagaagat	aatgagagaa	5700
ttaatggggg	ttatatattac	attatctctc	aactatgtag	cccatattac	tcaccctatg	5760
agtgaatctg	gaattgcttt	tcatgtgaaa	tcattgtggg	ctatgagttt	acaatactgc	5820
aaactgtgtt	attttatcta	aaccattgct	taatgagtgt	gtttttccat	gaatgaatat	5880
accgtgggtc	atatgttagc	atggcagcat	tttcagatag	ctttttgttt	gttgggaagt	5940
tgggggtttt	gggggagggg	gagtattagt	acgttgcatg	gaatagccta	ctttataatg	6000
atgggaatgc	tttttctttt	gttttgggat	tttttttttt	gaagtgaaat	ttaacttttt	6060
gtgccagtag	tactattata	cccatcttca	gtgtcttact	tgtactgtat	caaattccat	6120
accctcattt	aattcttaat	aaaactgttc	acttgtaaaa	aaaaaaaaaa	aaaaaaaaaa	6180
aaaaaaaaaa						6189

<210> 9
 <211> 5490
 <212> DNA
 <213> Homo sapiens

<400> 9

cgccccgccca	gccccggggg	cagggaaagc	ctaaattacg	gaattaccgc	gagcaaggag	60
cgcggaatcg	gggagcgtcc	ggagctagct	ggatcctcta	ggcaggatgg	tgatgggaat	120
ctttgcaaata	tgtatcttct	gtttgaaagt	gaagtactta	cctcagcagc	agaagaaaaa	180
gctacaaact	gacattaagg	aaaatggcgg	aaagttttcc	ttttcgttaa	atcctcagtg	240
cacacatata	atcttagata	atgctgatgt	tctgagtcag	taccaactga	attctatcca	300
aaagaaccac	gttcatattg	caaaccacaga	ttttatatgg	aaatctatca	gagaaaagag	360
actcttggat	gtaaagaatt	atgataccta	taagcccctg	gacatcacac	cacctcctga	420
tcagaaggcg	agcagttctg	aagtgaatac	agaaggctta	tgcccggaac	gtgccacaga	480
ggaggaagac	actgtggaac	tcactgagtt	tggtatgcag	aatgttgaaa	ttcctcatct	540
tcctcaagat	tttgaagttg	caaaatataa	caccttggag	aaagtgggaa	tggagggagg	600
ccaggaagct	gtggtggtgg	agcttcagtg	ttcgcgggac	tccagggact	gtcctttcct	660
gatataccta	cacttcctcc	tggatgatgg	catggagact	agaagacagt	ttgctataaa	720
gaaaacctct	gaagatgcaa	gtgaatactt	tgaataattac	attgaagaac	tgaagaaaca	780
aggatttcta	ctaagagAAC	atttcacacc	tgaagcaacc	caattagcat	ctgaacaatt	840
gcaagcattg	cttttggagg	aagtcattga	ttcaagcact	ctgagccaag	aggtgagcga	900
tttagtagag	atgatttggg	cagaggccct	gggccacctg	gaacacatgc	ttctcaagcc	960
agtgaacagg	attagcctca	acgatgtgag	caaggcagag	gggattctcc	ttctagtaaa	1020
ggcagcactg	aaaaatggag	aaacagcaga	gcaattgcaa	aagatgatga	cagagtttta	1080
cagactgata	cctcacaaag	gcacaatgcc	caaagaagtg	aacctgggac	tattggctaa	1140
gaaagcagac	ctctgccagc	taataagaga	catggttaat	gtctgtgaaa	ctaatttgtc	1200
caaaccacaac	ccaccatccc	tggccaaata	ccgagctttg	aggtgcaaaa	ttgagcatgt	1260
tgaacagaat	actgaagaat	ttctcagggt	tagaaaagag	gttttgcaga	atcatcacag	1320
taagagccca	gtggatgtct	tgcagatatt	tagagttggc	agagtgaatg	aaaccacaga	1380
gtttttgagc	aaacttggtg	atgtgaggcc	cttgttgcac	ggttctcctg	tacaaaacat	1440
cgtgggaatc	ttgtgtcgag	ggttgctttt	acccaaagta	gtggaagatc	gtggtgtgca	1500
aagaacagac	gtcggaaacc	ttggaagtgg	gattttatttc	agtgattcgc	tcagtacaag	1560
tatcaagtac	tcacaccgag	gagagacaga	tggcaccaga	ctcctgctca	tttgtgacgt	1620
agccctcgga	aagtgtatgg	acttacatga	gaaggacttt	cccttaactg	aagcaccacc	1680
aggctacgac	agtgtgcatg	gagtttcaca	aacagcctct	gtcaccacag	actttgagga	1740
tgatgaattt	gttgtctata	aaaccaatca	ggttaaaatg	aaatatatta	ttaaattttc	1800
catgcctgga	gatcagataa	aggactttca	tcctagtgat	catactgaat	tagaggaata	1860
cagacctgag	ttttcaaatt	tttcaaaggt	tgaagattac	cagttaccag	atgccaaaac	1920
ttccagcagc	accaaggccg	gcctccagga	tgccctctggg	aacttggttc	ctctggagga	1980

tgtccacatc	aaagggagaa	tcatagacac	tgtagcccag	gtcattgttt	ttcagacata	2040
cacaaataaa	agtcacgtgc	ccattgaggc	aaaatatatc	tttccttttg	atgacaaggc	2100
cgctgtgtgt	ggcttcgaag	ccttcatcaa	tgggaagcac	atagttggag	agattaaaga	2160
gaaggaagaa	gcccagcaag	agtacctaga	agccgtgacc	cagggccatg	gcgcttacct	2220
gatgagtcag	gatgctccgg	acgttttttac	tgtaagtgtt	ggaaacttac	cccctaaggc	2280
taaggttctt	ataaaaatta	cctacatcac	agaactcagc	atcctgggca	ctggttggtgt	2340
ctttttcatg	cccgccaccg	tagcacctg	gcaacaggac	aaggctttga	atgaaaacct	2400
tcaggataca	gtagagaaga	tttgtataaa	agaaatagga	acaaagcaaa	gcttctcttt	2460
gactatgtct	attgagatgc	cgtatgtgat	tgaattcatt	ttcagtgata	cacatgaact	2520
gaaacaaaag	cgcacagact	gcaaagctgt	cattagcacc	atggaaggca	gctccttaga	2580
cagcagtgga	ttttctctcc	acatcggttt	gtctgctgcc	tatctcccaa	gaatgtgggt	2640
tgaaaaacat	ccagaaaaag	aaagcgaggc	ttgcatgctt	gtctttcaac	ccgatctcga	2700
tgtcgacctc	cctgacctag	ccagtgagag	cgaagtgatt	atttgtcttg	actgctccag	2760
ttccatggag	ggtgtgacat	tcttgcaagc	caagcaaate	accttgcatg	cgctgtcctt	2820
ggtgggtgag	aagcagaaag	taaatattat	ccagttcggc	acagggtaca	aggagctatt	2880
ttcgtatcct	aagcatatca	caagcaatac	cacggcagca	gagttcatca	tgtctgccac	2940
acctaccatg	gggaacacag	acttctggaa	aacactccga	tatcttagct	tattgtaccc	3000
tgctcgaggg	tcacggaaca	tcctcctggg	gtctgatggg	cacctccagg	atgagagcct	3060
gacattacag	ctcgtgaaga	ggagccgccc	gcacaccagg	ttattcgcct	gcggtatcgg	3120
ttctacagca	aatcgtcacg	tcttaaggat	tttgtcccag	tgtgggtgccg	gagtatttga	3180
atattttaat	gcaaaatcca	agcatagttg	gagaaaacag	atagaagacc	aatgaccag	3240
gctatgttct	ccgagttgcc	actctgtctc	cgtcaaatgg	cagcaactca	atccagatgc	3300
gcccagagcc	ctgcaggccc	cagcccaggt	gccatccttg	tttcgcaatg	atcgactcct	3360
tgtctatgga	ttcattcctc	actgcacaca	agcaactctg	tgtgcactaa	ttcaagagaa	3420
agaattttgt	acaatggtgt	cgactactga	gcttcagaag	acaactggaa	ctatgatcca	3480
caagctggca	gcccagagctc	taatcagaga	ttatgaagat	ggcattcttc	acgaaaatga	3540
aaccagtcac	gagatgaaaa	aacaaacctt	gaaatctctg	attattaaac	tcagtaaaga	3600
aaactctctc	ataacacaat	ttacaagctt	tgtggcagtt	gagaaaaggg	atgagaatga	3660
gtcgcccttt	cctgatattc	caaaagtttc	tgaacttatt	gccaaagaag	atgtagactt	3720
cctgccctac	atgagctggc	agggggagcc	ccaagaagcc	gtcaggaacc	agtctctttt	3780
agcatcctct	gagtggccag	aattacgttt	atccaaacga	aaacatagga	aaattccatt	3840
ttccaaaaga	aaaatggaat	tatctcagcc	agaagtttct	gaagattttg	aagaggatgg	3900
cttaggtgta	ctaccagctt	tcacatcaaa	tttggaacgt	ggaggtgtgg	aaaagctatt	3960
ggatttaagt	tggacagagt	catgtaaacc	aacagcaact	gaaccactat	ttaagaaagt	4020
cagtccatgg	gaaacatcta	cttctagctt	ttttcctatt	ttggctccgg	ccgttggttc	4080
ctatcttacc	ccgactaccc	gcgctcacag	tcctgcttcc	ttgtcttttg	cctcatatcg	4140
tcaggtagct	agtttcgggt	cagctgctcc	tcccagacag	tttgatgcat	ctcaattcag	4200
ccaaggccct	gtgcctggca	cttgtgctga	ctggatccca	cagtcggcgt	cttgtcccac	4260
aggacctccc	cagaaccac	cttctgcacc	ctattgtggc	attgtttttt	cagggagctc	4320

attaagctct	gcacagtctg	ctccactgca	acatcctgga	ggctttacta	ccaggccttc	4380
tgctggcacc	ttccctgagc	tggattctcc	ccagcttcat	ttctctcttc	ctacagaccc	4440
tgatcccatc	agagggtttg	ggtcttatca	tccctctgct	tactctcctt	ttcatTTTTca	4500
accttccgca	gcctctttga	ctgccaacct	taggctgcca	atggcctctg	ctttacctga	4560
ggctctttgc	agtcagtccc	ggactacccc	agtagatctc	tgtcttctag	aagaatcagt	4620
aggcagtctc	gaaggaagtc	gatgtcctgt	ctttgctttt	caaagttctg	acacagaaaag	4680
tgatgagcta	tcagaagtac	ttcaagacag	ctgcttttta	caaataaagt	gtgatacaaa	4740
agatgacagt	atcccgtgct	ttctggaatt	aaaagaagag	gatgaaatag	tgtgcacaca	4800
acactggcag	gatgctgtgc	cttggacaga	actcctcagt	ctacagacag	aggatggctt	4860
ctggaaactt	acaccagaac	tgggacttat	attaaatctt	aatacaaatg	gtttgcacag	4920
ctttcttaaa	caaaaaggca	ttcaatctct	aggtgtaaaa	ggaagagaat	gtctcctgga	4980
cctaattgcc	acaatgctgg	tactacagtt	tattcgcacc	aggttggaaa	aagagggaat	5040
agtgttcaaa	tcactgatga	aatggatga	cccttctatt	tccaggaata	ttccctgggc	5100
ttttgaggca	ataaagcaag	caagtgaatg	ggtaagaaga	actgaaggac	agtacccatc	5160
tatctgccca	cggcttgaac	tggggaacga	ctgggactct	gccaccaagc	agttgctggg	5220
actccagccc	ataagcactg	tgtccctctc	tcatagagtc	ctccattaca	gtcaaggcta	5280
agtcaaatga	aactgaatTT	taaactTTTT	gcatgcttct	atgtagaaaa	taatcaaatg	5340
ataatagata	attataatga	aacttcatta	aggtttcatt	cagtgtagca	attactgtct	5400
ttaaaaatta	agtggaagaa	gaattacttt	aatcaactaa	caagcaataa	taaaatgaaa	5460
cttaaaaataa	aaaaaaaaaa	aaaaaaaaaa				5490

CLAIMS

1. Use of a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor in the manufacture of a medicament for the treatment of cancer cells defective in homologous recombination,
5 wherein the cancer cells have a defect in a gene which mediates homologous recombination selected from the group consisting of XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1,
10 FANCD2, FANCE, FANCF, FANCG, RAD1 and RAD9
2. Use according to claim 1 wherein the PARP-1 inhibitor is selected from the group consisting of benzimidazole-carboxamides, quinazolin-4-[3H]-ones and isoquinolone derivatives.
15
3. Use according to claim 1 wherein the PARP-1 inhibitor is selected from the group consisting of 2-(4-hydroxyphenyl)benzimidazole-4-carboxamide, 8-hydroxy-2-methylquinazolin-4-[3H]one, 6(5H)phenanthridinone, 3-aminobenzamide, benzimidazole-4-carboxamides and tricyclic lactam indoles.
20
4. The use as claimed in any one of claims 1 to 3 wherein the cancer cells defective in homologous recombination are partially deficient in homologous recombination.
5. The use as claimed in any one of claims 1 to 3 wherein the cancer cells defective
25 in homologous recombination are totally deficient in homologous recombination.
6. The use as claimed in any one of claims 1 to 5 wherein the defect is a mutation in a gene encoding a protein involved in homologous recombination.
- 30 7. The use as claimed in any one of claims 1 to 5 wherein the defect is the absence of a gene encoding a protein involved in homologous recombination.

8. The use as claimed in any one of claims 1 to 5 wherein the defect is in the expression of a gene encoding a protein involved in homologous recombination.

9. The use as claimed in any one of claims 1 to 8 wherein the cancer is selected from the group consisting of lung, colon, pancreatic, gastric, ovarian, cervical, breast and prostate cancer.

10. The use as claimed in any one of claims 1 to 9 wherein the cancer is in a human.

10 11. The use as claimed in any of claims 1 to 10 wherein the cancer is gene-linked hereditary cancer.

12. The use as claimed in claim 11 wherein the cancer is breast cancer.

15 13. The use as claimed in any of claims 1 to 12 wherein the cancer cells to be treated are defective in BRCA1 expression.

14. The use as claimed in any of claims 1 to 12 wherein the cancer cells to be treated are defective in BRCA2 expression.

20

15. The use as claimed in claim 13 or 14 wherein the cancer cells are partially deficient in BRCA1 and/or BRCA2 expression.

16. The use as claimed in claim 13 or 14 wherein the cancer cells are totally deficient in BRCA1 and/or BRCA2 expression.

25

17. The use as claimed in claim 6 wherein the gene that mediates homologous recombination is a tumour suppressor gene.

30 18. The use as claimed in claim 17 wherein the tumour suppressor gene is BRCA1.

19. The use as claimed in claim 17 wherein the tumour suppressor gene is BRCA2

20. Use of a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor for the treatment of cancer cells defective in homologous recombination, wherein the cancer cells have a defect in a gene which mediates homologous recombination selected from the group consisting of XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1 and RAD9.

21. The use according to claim 20 wherein the PARP-1 inhibitor is selected from the group consisting of: benzimidazole-carboxamides, quinazolin-4-[3H]-ones and isoquinolone derivatives.

22. The use according to claim 20 wherein the P ARP-1 inhibitor is selected from the group consisting of: 2-(4-hydroxyphenyl)benzimidazole-4-carboxamide, 8-hydroxy-2-methylquinazolin-4-[3H]one, 6(5H)phenanthridinone, 3-aminobenzamide, benzimidazole-4-carboxamides and tricyclic lactam indoles.

23. The use as claimed in any one of claims 20 to 22 wherein the cancer cells defective in homologous recombination are partially deficient in homologous recombination.

24. The use as claimed in any one of claims 20 to 22 wherein the cancer cells defective in homologous recombination are totally deficient in homologous recombination.

25. The use as claimed in any one of claims 20 to 24 wherein the defect is a mutation in a gene encoding a protein involved in homologous recombination.

26. The use as claimed in any one of claims 20 to 24 wherein the defect is the absence of a gene encoding a protein involved in homologous recombination.

27. The use as claimed in any one of claims 20 to 24 wherein the defect is in the
5 expression of a gene encoding a protein involved in homologous recombination.

28. The use as claimed in any one of claims 20 to 27 wherein the cancer cells are selected from the group consisting of: lung, colon, pancreatic, gastric, ovarian, cervical, breast and prostate cancer cells.

10

29. The use as claimed in any one of claims 20 to 28 wherein the cancer cells are in a human.

15

30. The use as claimed in any one of claims 20 to 29 wherein the cancer cells are from a gene-linked hereditary cancer.

31. The use as claimed in claim 30 wherein the cancer cells are breast cancer cells.

20

32. The use as claimed in any one of claims 20 to 31 wherein the cancer cells to be treated are defective in BRCA1 expression.

33. The use as claimed in any one of claims 20 to 32 wherein the cancer cells to be treated are defective in BRCA2 expression.

25

34. The use as claimed in claim 32 or 33 wherein the cancer cells are partially deficient in BRCA1 and/or BRCA2 expression.

35. The use as claimed in claim 32 or 33 wherein the cancer cells are totally deficient in BRCA1 and/or BRCA2 expression.

30

36. The use as claimed in claim 20 wherein the gene that mediates homologous recombination is a tumour suppressor gene.

37. The use as claimed in claim 36 wherein the tumour suppressor gene is BRCA 1.

5

38. The use as claimed in claim 36 wherein the tumour suppressor gene is BRCA2.

5 Figure 1.




Figure 2.




Figure 3




Figure 4






Figure 5A



V-C8



BRCA2 defective

HR

FIG. 5B to E





FIG. 6

8/20







FIG. 7




Fig. 8

FIGURE 9

1 cgcccgccca gccccggggg cagggaaagc ctaaattacg gaattaccgc gagcaaggag
61 cgcggaatcg gggagcgtcc ggagctagct ggatcctcta ggcaggatgg tgatgggaat
121 ctttgcaa at tgtatcttct gtttgaaagt gaagtactta cctcagcagc agaagaaaaa
181 gctacaaact gacattaagg aaaatggcgg aaagttttcc tttcgttaa atcctcagt
241 cacacatata atcttagata atgctgatgt tctgagtcag taccaactga attctatcca
301 aaagaaccac gttcatattg caaaccaga ttttatatgg aaatctatca gagaaaagag
361 actcttgat gtaaagaatt atgacctta taagccccctg gacatcacac cacctcctga
421 tcagaaggcg agcagttctg aagtga aaac agaaggtcta tgcccgga gtgccacaga
481 ggaggaagac actgtggaac tctactgagtt tggtatgcag aatgttgaaa ttctcatct
541 tctcaagat tttgaagttg caaatataa caccttgag aaagtgggaa tggagggagg
601 ccaggaagct gtggtggtgg agcttcagt ttcgcgggac tccagggact gtccttct
661 gatacctca cacttctcc tggatgatgg catggagact agaagacagt ttgctataaa
721 gaaaacctct gaagatgcaa gtgaatactt tga aaattac attgaagaac tgaagaaca
781 aggatttcta ctaagagaac atttcacacc tgaagcaacc caattagcat ctgaacaatt
841 gcaagcattg ctttgagg aagtcagaa tcaagcact ctgagccaag aggtgagcga
901 ttagtagag atgattggg cagaggccct gggccacctg gaacacatgc ttctcaagcc
961 agtgaacagg attagcctca acgatgtgag caaggcagag gggattctcc ttctagtaa
1021 ggcagcactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagagttta
1081 cagactgata cctcacaag gcacaatgcc caaagaagt aacctgggac tattggctaa
1141 gaaagcagac ctctgccagc taataagaga catggtta at gtctgtgaaa ctaattgtc
1201 caaaccaac ccaccatccc tggccaaata ccgagcttg aggtgcaaaa ttgagcatgt
1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag gtttgcaga atcatcacag
1321 taagagccca gtggatgtct tgcagatatt tagagttggc agagtgaatg aaaccacaga
1381 gttttgagc aaacttggt atgtgaggcc ctgttgcat ggtctctctg taaaaacat
1441 cgtgggaatc ttgtgtcag ggttgcttt acccaaagta gtggaagatc gtggtgtgca
1501 aagaacagac gtcggaaacc ttggaagtgg gatttattc agtgattcgc tcagtacaag
1561 tatcaagtac tcacaccgg gagagacaga tggcaccaga ctctgtctca tttgtgacgt
1621 agccctcgga aagtgtatgg acttacatga gaaggacttt tcttaactg aagcaccacc
1681 aggtacgac agtgtgcatg gagttcaca aacagcctct gtcaccacag acttgagga
1741 tgatgaattt gttgtctata aaaccaatca ggttaaatg aatatatta ttaaatttc
1801 catgcctgga gatcagataa aggacttca tctagtgtat catactgaat tagaggaata
1861 cagacctgag tttcaaatt tttcaaggt tgaagattac cagttaccag atgcaaaaac
1921 ttccagcagc accaaggccg gcctccagga tgcttctggg aacttggtc ctctggagga
1981 tgtccacatc aaaggagaa tcatagacac ttagccag gtcattgtt ttacagacata
2041 cacaataaaa agtcacgtgc ccattgagc aaaatatatc ttcttttg atgacaaggc
2101 cgctgtgtgt ggctcgaag cttcatcaa tgggaagcac atagttggag agattaaaga
2161 gaaggaagaa gccagcaag agtacctaga agccgtgacc cagggccatg gcgcttacct
2221 gatgagtcag gatgctccg acgtttttac tgaagtgtt ggaaacttac cccctaaggc
2281 taaggttctt ataaaaatta cctacatcac agaactcagc atcctgggca ctgttggtgt
2341 cttttcatg cccgccaccg tagcaccctg gcaacaggac aaggcttga atgaaaacct
2401 tcaggataca gtagagaaga tttgtataaa agaaatagga acaaagcaaa gcttcttt
2461 gactatgtct attgagatgc cgtacgtgat tgaattcatt ttactgata ctcatgaact
2521 gaaacaaaag cgcacagact gcaaagctgt cattagcacc atggaaggca gctccttaga
2581 cagcagtga tttctctcc acatcggtt gtctgtgcc tatctccaa gaatgtgggt
2641 tga aaaacat ccagaaaag aaagcgaggc ttgcatgctt gtcttcaac ccgactcga
2701 tgtcgacct cctgacctag ccaatgagag cgaagtgatt attgtcttg actgctccag
2761 ttccatggag ggtgtgacat tcttgcaagc caaggaaatc gccttgcag cgctgtcctt

11/20

2821 ggtgggtgag aagcagaaag taaatattat ccagttcggc acaggttaca aggagctatt
2881 ttcgtatcct aagcatatca caagcaatac cgcggcagca gagttcatca tgtctgccac
2941 acctaccatg gggaacacag acttctggaa aacactccga tatcttagct tattgtaccc
3001 tgctcgaggg tcacggaaca tcctctggt gtctgatggg cacctccagg atgagagcct
3061 gacattacag ctctgaaga ggagccgccc gcacaccagg ttattgcct gcggtatcgg
3121 ttctacagca aatcgtcacg tcttaaggat ttgtcccag tgtggtgccg gagtattga
3181 atattttaat gcaaaatcca agcatagttg gagaaaacag atagaagacc aaatgaccag
3241 gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc
3301 gcccgaggcc ctgcaggccc cagcccaggt gccatccttg ttctgcaatg atcgactcct
3361 tgtctatgga ttattctctc actgcacaca ggcaactctg tgtgcactaa ttcaagagaa
3421 agaattttgt acaatggtgt cgactactga gcttcagaag acaactggaa ctatgatcca
3481 caagctggca gcccagctc taatcagaga ttatgaagat ggcatcttc acgaaaatga
3541 aaccagtcat gagatgaaaa acaaacctt gaaatctctg attattaaac tcagtaaaga
3601 aaactctctc ataacacaat ttacaagctt tgtggcagtt gagaaaagg atgagaatga
3661 gtcacctttt cctgatattc caaaagtctc tgaacttatt gccaaagaag atgtagactt
3721 cctgccctac atgagctggc agggggaacc ccaagaagcc gtcaggaacc agtctctttt
3781 agcatcctct gaggggccag aattacgtt atccaaacga aaacatagga aaattccatt
3841 ttccaaaaga aaaatggaat tatctcagcc agaagttct gaagatttg aagaggatgc
3901 cttaggtgta ctaccagctt tcacatcaa tttggaacgt ggacgtgtgg aaaagctatt
3961 ggatttaagt tggacagagt catgtaaac aacagcaact gaaccactat ttaagaaagt
4021 cagtccatgg gaaacatcta ctctagctt ttctctatt ttggctccgg ccgttggtc
4081 ctatcttacc ccgactacc gcgtcacag tctgtctcc ttgtctttg cctcatatc
4141 tcaggtagct agttcgggt cagctgtctc tcccagacag ttgatgcat ctcaattcag
4201 ccaaggccct gtgcctggca ctgtgtctga ctggatcca cagtcggcgt ctgtcccac
4261 aggacctccc cagaaccac ctctgcacc ctattgtggc attgttttt caggagctc
4321 attaagctct gcacagtctg ctccactgca acatctgga ggctttacta ccaggcctc
4381 tgctggcacc ttccctgagc tggattctcc ccagcttcat ttctctctc ctacagacc
4441 tgatcccatc agaggtttg ggtcttatca tccctctgt tactctctt ttattttca
4501 accttccgca gcctctttga ctgccaacct taggctgcca atggcctctg ctttacctga
4561 ggctctttgc agtcagtcg ggactacccc agtagatctc tgtcttctag aagaatcagt
4621 aggcagtctc gaaggaagtc gatgtcctgt cttgtcttt caaagttctg acacagaaag
4681 tgatgagcta tcagaagtac ttcaagacag ctgctttta caaataaaat gtgatacaaa
4741 agatgacagt atcccgtgct ttctggaagt aaaagaagag gatgaaatag tgtgcacaca
4801 aactggcag gatgctgtgc cttggacaga actcctcagt ctacagacag aggatggctt
4861 ctggaaactt acaccagaac tgggacttat attaaatctt aatacaaatg gttgcacag
4921 cttctttaa caaaaaggca ttcaatctct aggtgtaaaa ggaagagaat gtctcctgga
4981 cctaattgcc acaatgctgg tactacagtt tattcgcacc aggttggaag aagagggaat
5041 agtgttcaaa tctatgatga aaatggatga ccttctatt tccaggaata ttccctgggc
5101 ttttgaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc
5161 tatctgcca cggcttgaa tggggaacga ctgggactct gccaccaagc agttgctggg
5221 actccagccc ataagcactg tgtccctct tcatagagtc ctccattaca gtcaaggcta
5281 agtcaaatga aactgaattt taaactttt gcattgctt atgtagaaaa taatcaaatg
5341 ataatagata cttataatga aacttatta aggtttcatt cagtgtagca attactgtct
5401 ttaaaaatta agtgaagaa gaattacttt aatcaactaa caagcaataa taaatgaaa
5461 cttaaaat

Figure 10

1 ctagaattca gcggccgctg aattctaggc ggcgcggcgg cgacggagca ccggcggcgg
61 cagggcgaga gcattaatg aaagcaaaag agttaataat ggcaacacgg ctccagaaga
121 ctcttccctt gccaaagaaa ctctagatg ccagagacag gagtcgaaaa agatgcctgt
181 ggctggagga aaagctaata aggacaggac agaagacaag caagatggta tgccaggaag
241 gtcattggcc agcaaaaggg tctctgaatc tgtgaaggcc ttgctgttaa agggcaaagc
301 tctgtggac ccagagtga cagccaaggc ggggaaggct catgtgtatt gtgaaggaaa
361 tgatgtctat gatgtcatgc taaatcagac caatctccag ttcaacaaca acaagtacta
421 tctgattcag ctattagaag atgatgcca gaggaacttc agtggttga tgagatggg
481 ccgagttggg aaaatgggac agcacagcct ggtggcttgc tcaggcaatc tcaacaaggc
541 caaggaaatc ttccagaaga aattcctga caaacgaaa aacaattggg aagatcgaga
601 aaagtttgag aaggtgcctg gaaaatatga tatgtacag atggactatg ccaccaatac
661 tcaggatgaa gaggaacaa aaaaagagga atctcttaa tctccctga agccagagtc
721 acagctagat ctccgggtac aggagttaat aaagttgac tgtaattgtc aggccatgga
781 agaatgatg atggaaatga agtataatac caagaaagcc ccacttggga agctgacagt
841 ggcacaaatc aaggcaggtt accagtctct taagaagatt gaggattgta tccgggctgg
901 ccagcatgga cgagctctca tggaagcatg caatgaatc tacaccagga ttccgcatga
961 ctttgactc cgtactctc cactaatccg gacacagaag gaactgtcag aaaaaataca
1021 attactagag gcttgggag acattgaaat tgctattaag ctggtgaaaa cagagctaca
1081 aagcccagaa caccattgg accaacata tagaaaccta cattgtgcct tgcgccccct
1141 tgaccatgaa agttacgagt tcaaagtga tcccagtag ctacaatcta cccatgctcc
1201 cacacacagc gactatacca tgacctgct ggattgttt gaagtggaga aggatggta
1261 gaaagaagcc ttcagagagg acctcataa caggatgctt ctatggcatg gttccaggat
1321 gagtaactgg gtgggaatct tgagccatgg gcttcgaatt gccaccctg aagctccat
1381 cacaggttac atgttggga aaggaatcta cttgctgac atgtctcca agagtccaa
1441 ttactgctt gcctctgcc taaagaatac aggactgctg ctcttatcag aggtagctct
1501 aggtcagtgt aatgaactac tagaggccaa tctaaggcc gaaggattgc ttcaaggtaa
1561 acatagcacc aaggggctgg gcaagatggc tccagttct gccacttcg tcacctgaa
1621 tgggagtaca gtgccattag gaccagcaag tgacacagga attctgaatc cagatggta
1681 taccctcaac tacaatgaat atattgtata taacccaac caggtccgta tgcggtacct
1741 tttaaagggt cagttaatt tcttcagct gtggtgaatg ttgatctta ataaaccaga
1801 gatctgatct tcaagcaaga aaataagcag tgtgtactt gtgaatttg tgatattta
1861 tgtaataaaa actgtacagg tctaaaaaaa aaaaaaaaaa aaaaaaaaaa

//

Figure 11

1 tgggactggt cgcctgactc ggcctgcccc agcctctgct tcacccact ggtggccaaa
61 tagccgatgt ctaatcccc acacaagctc atccccggcc tctgggattg ttgggaattc
121 tctccctaat tcacgcctga ggctcatgga gaggtagtag acctgggact gccctgggag
181 gcgcacacaa ccaggccggg tggcagccag gacctctccc atgtccctgc tttcttggc
241 catggctcca aagccgaagc cctgggtaca gactgagggc cctgagaaga agaagggccg
301 gcaggcagga agggaggagg accccttccg ctccaccgt gaggcctca aggccatacc
361 cgcagagaag cgcataatcc gctggatcc aacatgtcca ctacagcaga acccgggac
421 ccaggtgtat gaggactaca actgcacct gaaccagacc aacatcgaga acaacaacaa
481 caagttctac atcatccagc tgctccaaga cagcaaccgc ttcttcacct gctggaaccg
541 ctggggccgt gtgggagagg tcggccagtc aaagatcaac cacttcacaa ggctagaaga
601 tgcaaagaag gactttgaga agaaattcg ggaaaagacc aagaacaact gggcagagcg
661 ggaccacttt gtgtctcacc cgggcaagta cacacttacc gaagtacagg cagaggatga
721 ggcccaggaa gctgtggtga aggtggacag aggcccagtg aggactgtga ctaagcgggt
781 gcagccctgc tccctggacc cagccacgca gaagctcacc actaacatct tcagcaagga
841 gatgttcaag aacaccatgg cctcatgga cctggatgtg aagaagatgc ccctgggaaa
901 gctgagcaag caacagattg cacggggttt cgaggccttg gaggcgctgg aggaggccct
961 gaaaggcccc acggatggtg gccaaagcct ggaggagctg tctcacact ttacaccgt
1021 catccgcac aacttcggcc acagccagcc cccgccatc aattccctg agcttctgca
1081 ggccaagaag gacatgctgc tgggtctggc ggacatcgag ctggcccagg ccctgcaggc
1141 agtctctgag caggagaaga cggtaggga ggtgccacac ccctggacc gagactacca
1201 gcttctcaag tgccagctgc agctgctaga ctctggagca cctgagtaca agtgataca
1261 gacctactta gaacagactg gcagcaacca caggtgccct acactcaac acatctggaa
1321 agtaaaccac gaaggggagg aagacagatt ccaggccac tccaaactgg gtaatcgaa
1381 gctgctgtgg catggcacca acatggcgt ggtggccgc atctcacta gtgggctccg
1441 catcatgcca cattctggtg ggcgtgttg caagggcacc tactttgcct cagagaacag
1501 caagtcagct ggatatgta ttggcatgaa gtgtggggcc caccatgtc gctacatgtt
1561 cctgggtgag gtggccctgg gcagagagca ccatacaac acggacaacc ccagcttgaa
1621 gagccacct cctggcttcg acagtgtcat tgcccaggc cacaccgagc ctgatccgac
1681 ccaggacact gaggtaggc tgatggcca gcaagtgtg gtgcccagg gccagcctgt
1741 gccctgcca gaggtagca gctccacatt ctcccagagc gaggacctca tctaccagga
1801 gagccagtgt cgcctgcgt acctgtgga ggtccacctc tgagtgcgc ccctgtccc
1861 cggggtcctg caaggtgga ctgtgatct caatcatct gccatctct ggtacccta
1921 tatcactct tttttcaag aatacaatac gttgtgtta actatagtca ccatgctga
1981 caagatccct gaacttatgc ctctaactg aaattttgta ttcttgaca catctgcca
2041 gtccctctcc tcccagcca tggtaccag catttgactc ttacttgta taagggcagc
2101 tttataggt tccacatgta agtgagatca tgcagtgtt gtcttctgt gcctggctta
2161 ttactcag cataatgtc accgggttca cccatgttt cataaatgac aagatttct
2221 ccttataaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa

Figure 12

14/20

```

1  cgaagatggc ggcgtcgcgt cgctctcagc atcatcacca ccatcatcaa caacagctcc
61  agcccgcccc aggggcttca gcgccggcgc cgccacctcc tccccactc agccctggcc
121 tggccccggg gaccacccca gcctctccca cggccagcgg cctggcccc ttcgcctccc
181 cgcggcacgg cctagcgctg ccggaggggg atggcagtcg ggatccgccc gacaggcccc
241 gatccccgga cccggttgac ggtaccagct gttgcagtac caccagcaca atctgtaccg
301 tcgccggcgc tcccgtgggt ccagcggttt ctacttcac tgcgctggg gtcgctccca
361 acccagccgg cagtggcagt aacaattcac cgtcgtcctc ttcttccccg acttcttctt
421 catcttcttc tccatcctcc cctggatcga gcttggcggg gagccccgag gcggccggag
481 ttagcagcac agcaccactg gggcctgggg cagcaggacc tgggacaggg gtcccagcag
541 tgagcggggc cctacgggaa ctgctggagg cctgtcgcaa tggggacgtg tcccgggtaa
601 agaggctggg ggacgcggca aacgtaaata caaaggacat ggccggccgg aagtcttctc
661 ccctgcactt cgctgcaggt tttggaagga aggatgttgt agaactta ctacagatgg
721 gtgctaattg ccacgctcgt gatgatggag gtctcatccc gcttcataat gcctgttctt
781 ttggccatgc tgaggttgtg agtctgttat tgtgccaagg agctgatcca aatgccaggg
841 ataactggaa ctatacacct ctgcatgaag ctgctattaa agggaagatc gatgtgtgca
901 ttgtgctgct gcagcacgga gctgacccaa acattcggaa cactgatggg aaatcagccc
961 tggacctggc agatccttca gcaaaagctg tccttacagg tgaatacaag aaagacgaac
1021 tcctagaagc tgctaggagt ggtaataaag aaaaactaat ggctttactg actcctctaa
1081 atgtgaattg ccatgcaagt gatgggcgaa agtcgactcc tttacatcta gcagcgggct
1141 acaacagagt tcgaatagtt cagcttcttc ttcagcatgg tgctgatgtt catgcaaaag
1201 acaaagggtg acttgtgcct cttcataatg catgttcata tggacattat gaagtcacag
1261 aactgctact aaagcatgga gcttgtgtta atgccatgga tctctggcag tttactccac
1321 tgcacgaggc tgcttccaag aaccgtgtag aagtctgctc tttgttactt agccatggcg
1381 ctgatcctac gttagtcaac tgccatggca aaagtgtgtt ggatatggct ccaactccgg
1441 agcttaggga gagattgact tatgaattta aaggtcattc tttactacaa gcagccagag
1501 aagcagactt agctaaagtt aaaaaaacac tcgctctgga aatcattaat ttcaaacaac
1561 cgcagtctca tgaaacagca ctgcactgtg ctgtggcctc tctgcatccc aaacgtaaac
1621 aagtgcagca attgttactt agaaaaggag caaatgttaa tgaaaaaat aaagatttca
1681 tgactcccct gcatgttgca gccgaaagag ccataatga tgtcatggaa gttctgcata
1741 agcatggcgc caagatgaat gcaactggca cccttgggtc gactgctttg catagagccg
1801 ccctagcagg ccacctgcag acctgccgcc tcctgctgag ttacggctct gaccttcca
1861 tcatctcctt acaaggcttc acagcagcac agatgggcaa tgaagcagtg cagcagattc
1921 tgagtgtgag ttacggctct gaccttcca tcatctcctt acaaggcttc acagcagcac
1981 agatgggcaa tgaagcagtg cagcagattc tgagtgttca ttcgtagata gtgatcattc
2041 tacttcagcc ttaattggtg tcttgagacg ggaagattta gaaggaaatc tatccagcat
2101 gtcttctact tcaacatgaa gactacacct atactgactt ctgatgttga ttatcgaactc
2161 ttagaggcat ctaaagctgg agacttgga actgtgaagc aactttgcag ctctcaaaat
2221 gtgaattgta gagacttaga gggccggcat tccacgccct tacacttcgc agcaggctac
2281 aacagagtac acctatacgt acttctgatg ttgattatcg actcttagag gcatctaaag
2341 ctggagactt ggaaactgtg aagcaacttt gcagctctca aaatgtgaat tgtagagact
2401 tagagggccg gcattccacg cccttacact tcgcagcagg ctacaaccgc gtgtctgttg
2461 tagagtacct gctacaccac ggtgccgatg tccatgccaa agacaagggt ggcttgggtg
2521 cccttcataa tgctgttca tatggacact atgaggtggc tgagctttta gtaaggcatg
2581 gggcttctgt caatgtggcg gacttatgga aatttaccct tctccatgaa gcagcagcta
2641 aaggaaagta tgaaatctgc aagctccttt taaaacatgg agcagatcca actaaaaaga
2701 acagagatgg aaatacacct ttggatttgg taaaggaagg agacacagat attcaggact
2761 tactgaaagg ggatgctgct ttgttggatg ctgccaagaa gggctgcctg gcaagagtgc
2821 agaagctctg taccacagag aatatcaact gcagagacac ccagggcaga aattcaacc
2881 ctctgcacct ggcagcaggc tataataacc tggaagtagc tgaatatctt ctagagcatg
2941 gagctgatgt taatgcccag gacaagggtg gtttaattcc tcttcataat gcggcatctt
3001 atgggcatgt tgacatagcg gctttattga taaaatacaa cacgtgtgta aatgcaacag
3061 ataagtgggc gtttactccc ctccatgaag cagcccagaa aggaaggacg cagctgtgcg
3121 ccctcctcct agcgcgatgt gcagacccca ccatgaagaa ccaggaaggc cagacgcctc
3181 tggatctggc aacagctgac gatatcagag ctttgcctgt agatgccatg cccccagagg
3241 ccttacctac ctgtttttaa cctcaggcta ctgtagtgag tgctctctg atctcaccag
3301 catccacccc ctctgcctc tcggctgcca gcagcataga caacctcact ggccctttag
3361 cagagttggc cgtaggagga gcctccaatg caggggatgg cgcgcgggga acagaaagga
3421 aggaaggaga agttgctggg cttgacatga atatcagcca atttctaaaa agccttggcc
3481 ttgaacacct tcgggatatc tttgaaacag aacagattac actagatgtg ttggctgata
3541 tgggtcatga agagttgaaa gaaataggca tcaatgcata tgggcaccgc cacaatttaa
3601 tcaaaggagt agaaagactc ttaggtggac aacaaggcac caatccttat ttgacttttc
3661 actgtgttaa tcagggaacg attttgcctg atcttgctcc agaagataaa gaatatcagt
3721 cagtggagaa agagatgcaa agtactattc gagaacacag agatgggtgg aatgctggcg
3781 gcatcttcaa cagatacaat gtcattcgaa ttcaaaaagt tgtcaacaag aagttgaggg
3841 agcggttctg ccaccgacag aagggaagtgt ctgaggagaa tcacaaccat cacaatgagc

```

WO 2005/012524

PCT/GB2004/003235

15/20

3901 gcatgttggt tcatggttct cctttcatta atgccattat tcataaaggg tttgatgagc
3961 gacatgcata cataggagga atgtttgggg ccgggattta ttttgctgaa aactcctcaa
4021 aaagcaacca atatgtttat ggaattggag gaggaacagg ctgccctaca cacaaggaca
4081 ggtcatgcta tatatgtcac agacaaatgc tcttctgtag agtgaccctt gggaaatcct
4141 ttctgcagtt tagcaccatg aaaatggccc acgcgcctcc agggcaccac tcagtcattg
4201 gtagaccgag cgtcaatggg ctggcatatg ctgaatatgt catctacaga ggagaacagg
4261 cataccaga gtatcttata acttaccaga tcatgaagcc agaagcccct tcccagaccg
4321 caacagccgc agagcagaag acctagttaa tgcctgctgg tgaaggccag atcagatttc
4381 aacctgggac tggattacag aggattgttt ctaataacaa catcaatatt ctagaagtcc
4441 ctgacagcct agaaataagc tgtttgtctt ctataaagca ttgctatagt g

Figure 13

1 cgcgccgcct cgctagccga aacctgccc gccggtgccc ggccactgcg cacgcgcggg
61 acgacgtcac gtgcgtccc ggggctggac ggagctggca ggaggggcct tgccagcttc
121 cgccgccgcg tcgttcagg acccgacgg cggttcgcg ctgcctccgc cgccgcgggg
181 cagccggggg gcagggagcc cagcgagggg cgcgctggg cgcggccatg ggactgcgc
241 ggatccggtg acagcaggga gccaaagcggc ccgggccctg agcgctctt ctccggggg
301 cctcgccctc ctgctcgcg ggccggggct cctgctccg ttgctggcg ttttctggc
361 tgtggcgcg gccaggatca tgcgggtcg ccgctgcgc gccgggggag cggcctgcg
421 gagcgccgc gccgagggc tggagccgg cgcccgagag ctgttcgagg cgtgccgcaa
481 cggggacgtg gaacgagta agaggctgg gacgcctgag aaggtgaaca gccgcgacac
541 ggcgggcagg aaatccacc cgctgcact cgccgcaggt tttgggcgga aagacgtagt
601 tgaatattg ctccagaat gtgcaaatg ccaagcacgt gatgatggg gccttattc
661 tctcataat gcatgctct ttggtcatg tgaagtagt aatctctt tgcgacatg
721 tgcagacccc aatgctcgag ataattgaa ttatactct ctccatgaag ctgcaattaa
781 aggaaagatt gatgttgca ttgtctgtt acagcatgga gctgagccaa ccatccgaaa
841 tacagatgga aggacagcat tggatttagc agatccatc gccaaagcag tgcttactg
901 tgaatataag aaagatgaac tctagaaag tgccaggagt ggcaatgaag aaaaaatgat
961 ggctctact acaccattaa atgtcaact ccacgaagt gatggcagaa agtcaactc
1021 attacattg gcagcaggat ataacagagt aaagattga cagctgttac tgcaacatg
1081 agctgatgc catgctaaag ataaaggta tctggtacca ttacacatg cctgttctta
1141 tggctcatt gaagtaact aacttttgg caagcatgg gcctgtgta atgcaatga
1201 cttgtggcaa ttactctc tcatgaggc agcttctaag aacagggtg aagtatgtc
1261 tcttctctta agttatgtg cagacccaac actgctcaat tgcacaata aaagtgtat
1321 agacttggc cccacaccac agttaaaga aagattagca tatgaattt aaggccactc
1381 gttgctgca gctgcacgag aagctgatg tactcgaatc aaaaaacatc tctctctgga
1441 aatggtgaat ttcaagcat ctcaaacaca tgaacagca ttgcatttg ctgctgcac
1501 tccatatccc aaaagaaagc aaatatgtga actgttgcta agaaaaggag caaacatcaa
1561 tgaaaagact aaagaattct tgactcctc gcacgtggca tctgagaaag ctcataatga
1621 tgttgtgaa gtagtggtg aacatgaagc aaagggtta gctctggata atcttggtca
1681 gacttctta cacagagctg catattgtg tcatctaca acctgccgc tactcctgag
1741 ctatgggtg gatcctaaca ttataccct tcagggttt actgctttac agatgggaaa
1801 tgaaaatga cagcaactc tccaagagg tatctatta gtaattcag aggcagacag
1861 acaattgct gaagctgcaa aggtggaga tgcgaaact gtaaaaaaac tgtgtactg
1921 tcagagtgc aactgcagag acattgaagg gcgtcagtct acaccactc atttgcagc
1981 tgggtataac agagtgtcc tgggtgaata tctgtacag catggagctg atgtgcatg
2041 taaagataa ggaggcctt tacctttgca caatgcatg tcttatggac attatgaag
2101 tgcagaact cttgttaac atggagcagt agttaatga gctgattat ggaaattac
2161 acctttacat gaagcagcag caaaaggaaa atatgaaatt tgcaaacctc tgcctcagca
2221 tgggtcagac cctacaaaaa aaaacaggga tggaaatact ctttggatc ttgttaaaga
2281 tggagataca gatattcaag atctgcttag gggagatgca gcttgctag atgtgccaa
2341 gaagggtgt ttagccagag tgaagaagt gtctctct gataatgaa attgccgca
2401 tacciaaggc agacattcaa cacctttaca ttagcagct ggttataata attagaagt
2461 tgcagagtat ttgttacaac acggagctga tgtgaatgcc caagacaaag gaggacttat
2521 tctttacat aatgcagcat ctacgggca ttagatgta gcagctctac taataaagta
2581 taatgcatg gtcaatgcca cggacaaat ggcttcaca ctttgcacg aagcagccca
2641 aaaggacga acacagctt gtgcttgtt gtagcccat ggagctgacc cgactctaa
2701 aaatcaggaa ggacaaacac cttagattt agttcagca gatgatgta gcgctctct
2761 gacagcagc atgccccat ctgctctgc ctctgttac aagcctcaag tgctcaatg

17/20

2821 tgtgagaagc ccaggagcca ctgcagatgc tctctcttca ggtccatcta gcccataag
2881 cctttctgca gccagcagtc ttgacaactt atctgggagt tttcagaac tgtcttcagt
2941 agttagttca agtggaaacag aggggtgctc cagtttggag aaaaaggagg ttccaggagt
3001 agattttagc ataactcaat tcgtaaggaa tcttggactt gagcacctaa tggatatatt
3061 tgagagagaa cagatcactt tggatgtatt agttgagatg gggcacaagg agctgaagga
3121 gattggaatc aatgcttatg gacataggca caaactaatt aaaggagtcg agagacttat
3181 ctccggacaa caaggtctta acccatatct aactttgaac acctctggta gtggaacaat
3241 tcttatagat ctgtctcctg atgataaaga gtttcagtct gtggaggaag agatgcaaag
3301 tacagttcga gagcacagag atggagggtca tgcagggtga atcttcaaca gatacaatat
3361 tctcaagatt cagaaggttt gtaacaagaa actatgggaa agatacactc accggagaaa
3421 agaagtttct gaagaaaacc acaacctatgc caatgaacga atgctatttc atgggtctcc
3481 ttttgtgaat gcaattatcc acaaaggctt tgatgaaagg catgcgtaca taggtggtat
3541 gtttgagct ggcatttatt ttgctgaaaa ctcttccaaa agcaatcaat atgtatatgg
3601 aattggagga ggtactgggt gtccagtcca caaagacaga tcttgttaca ttgcccacag
3661 gcagctgctc tttgccggg taaccttggg aaagtcttc ctgcagtcca gtgcaatgaa
3721 aatggcacat tctctccag gtcactcact agtcactggg aggcccagtg taaatggcct
3781 agcattagct gaatatgtta ttacagagg agaacaggct tctctgagt atttaattac
3841 ttaccagatt atgaggcctg aaggtatggg cgtatggataa atagttattt taagaaacta
3901 attccactga acctaaaac atcaaagcag cagtggcctc tacgttttac tctttgctg
3961 aaaaaaaac atcttgccca caggcctgtg gcaaaaggat aaaaatgtga acgaagtta
4021 acattctgac ttgataaagc ttaataatg tacagtgttt tctaatatt tctgtttt
4081 tcagcacttt aacagatgcc attccagggt aaactgggtt gtctgtacta aattataaac
4141 agagttaact tgaacctttt atatgttatg cattgattct aacaaactgt aatgccctca
4201 acagaactaa tttactaat acaatactgt gttctttaa acacagcatt tacactgaat
4261 acaattcat ttgtaaaact gtaataaga gctttgtac tagccagta tttattaca
4321 ttgctttgta atataaatct gttttagaac tgcagcgggt tacaaaattt ttcatatgt
4381 attgttcat tatactcat cttacatcgt catgattgag tgatctttac atttgattcc
4441 agaggctatg ttcagtgtt agttgggaaa gattgagtta tcagatttaa ttgcccagatg
4501 ggagccttta tctgtcatta gaaatcttc tcatttaaga acttatgaat atgctgaaga
4561 ttaatttgt gatactttg tatgtatgag acacattcca aagagctcta actatgatag
4621 gtcctgatta ctaaagaagc ttcttactg gcctcaattt ctagctttca tgttgaaaa
4681 tttctgcag tcttctgtg aaaattagag caaagtctc ctgttttta gagaaactaa
4741 atcttctgt tgaacaatta ttgtgttctt tcatggaac ataagtagga tgtaacatt
4801 tccagggtgg gaagggtaat cctaaatcat tcccaatct attctaata cctaaatct
4861 aaaggggaaa aaaaaaatca caaacaggac tgggtagttt ttatcctaa gtatatttt
4921 tctgttctt tttacttggg ttattgctg tatttatagc caatctatac atcatggga
4981 aacttaacc agaactataa aatgtagttg ttccagtcct cttcaggcct cctgaatggg
5041 caagtgcagt gaaacagggt cttctgctc ctgggtttc tctccatgat gttatgcca
5101 attggaaata tgctgtcagt ttgtgcacca tatggtgacc acgctgtgc tcagttggc
5161 agctatagaa ggaaatgctg tccataaaa tgccatccct attctaata taacactctt
5221 ttccaggaag catgcttaag catcttgta cagagacata catccattat ggcttgcaa
5281 tctcttttat ttgtgactc tagtccctt caaagtcgag gaaagatctt tactactta
5341 atgaggacat tccccatcac tgtctgtacc agttcacctt tattttacgt ttattcagt
5401 ctgtaaatta actggccctt tgcagtaact tgtacataaa gtgctagaaa atcatgttc
5461 ttgtcctgag taagagttaa tcagagtaag tgcattctg gagttgttc tgtgatgtaa
5521 attatgatca ttatttaaga agtcaaatcc tgatcttgaa gtgctttta tacagctctc
5581 taataattac aaatatccga aagtcatttc ttggaacaca agtggagtat gccaaattt
5641 atatgaattt ttacagattat ctaagcttc aggtttata attagaagat aatgagagaa
5701 ttaatgggt ttatatttac attatctctc aactatgtag cccatattac tcaccctatg
5761 agtgaatctg gaattgctt tcatgtgaaa tcattgtgtt ctatgagttt acaatactgc

18/20

5821 aaactgtgtt atttatcta aaccattgct taatgagtgt gttttccat gaatgaatat
5881 accgtggttc atatgtagc atggcagcat ttcagatag cttttgttt gttgggaagt
5941 tggggtttg gggggagggg gagtattagt acgttgcag gaatagccta cttataatg
6001 atgggaatgc ttttctttt gtttgggat tttttttt gaagtgaaat ttaactttt
6061 gtgccagtag tactattata cccatcttca gtgtcttact tgtactgtat caaattccat
6121 accctcattt aattcttaat aaaactgttc acttgtaaaa aaaaaaaaaa aaaaaaaaaa
6181 aaaaaaaaaa

Figure 14

1 cgcccgccca gccccggggg cagggaagc ctaaattacg gaattaccgc gagcaaggag
61 cgcggaatcg gggagcgtcc ggagctagct ggatcctcta ggcaggatgg tgatgggaat
121 ctttgcaaat tgtatcttct gtttgaaagt gaagtactta cctcagcagc agaagaaaaa
181 gctacaaact gacattaagg aaaatggcgg aaagtttcc ttctgtaa atcctcagt
241 cacacatata atcttagata atgctgatgt tctgagtcag taccaactga attctatcca
301 aaagaaccac gtcatattg caaaccaga ttttatatgg aaatctatca gagaaaagag
361 actcttggat gtaaagaatt atgaccta taagcccctg gacatcacac cacctcctga
421 tcagaaggcg agcagttctg aagtgaaac agaaggtcta tgcccggaca gtgccacaga
481 ggaggaagac actgtggaac tctgaggtt tggtatgcag aatgttgaaa ttctcatct
541 tcctcaagat ttgaagttg caaatataa caccttggag aaagtgggaa tggagggagg
601 ccaggaagct gtggtggtg agcttcagt ttcgcgggac tccagggact gtccttct
661 gatcctca cacttctcc tggatgatgg catggagact agaagacagt ttgctataaa
721 gaaaacctct gaagatgcaa gtgaatactt tgaattac attgaagaac tgaagaaaca
781 aggatttcta ctaagagaac atttcacacc tgaagcaacc caattagcat ctgaacaatt
841 gcaagcattg ctttggagg aagtcataa ttcaagcact ctgagccaag aggtgagcga
901 tttagtagag atgatttggg cagaggccct gggccacctg gaacacatgc ttctcaagcc
961 agtgaacagg attagcctca acgatgtgag caaggcagag gggattctcc ttctagtaa
1021 ggcagcactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagagttta
1081 cagactgata cctcacaag gcacatgcc caaagaagt aacctgggac tattggctaa
1141 gaaagcagac ctctgccagc taataagaga catggtaat gtctgtgaaa ctaattgtc
1201 caaaccaac ccaccatccc tggccaaata ccgagcttg aggtgcaaaa ttgagcatgt
1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag gtttgcaga atcatcacag
1321 taagagccca gtgatgtct tgcagatatt tagagttggc agagtgaatg aaaccacaga
1381 gttttgagc aaacttggt atgtgaggcc ctgttgcat ggttctctg tacaaaacat
1441 cgtgggaatc ttgtgtcag ggttcttt acccaaagta gtggaagatc gtggtgtgca
1501 aagaacagac gtcggaaacc ttggaagtgg gattatttc agtgattcgc tcagtacaag
1561 tatcaagtac tcacaccgg gagagacaga tggcaccaga ctctgtctca tttgtgacgt
1621 agccctcgga aagtgtatgg acttacatga gaaggactt ccttaactg aagcaccacc
1681 aggctacgac agtgtcatg gagtttaca aacagcctct gtcaccacag actttgagga
1741 tgatgaattt gttgtctata aaaccaatca ggttaaatg aaatatatta ttaaatttc
1801 catgcctgga gatcagataa aggacttca tctagtgtat catactgaat tagaggaata
1861 cagacctgag tttcaaatt tttcaaagt tgaagattac cagttaccag atgcaaaaac
1921 ttccagcagc accaaggccg gcctccagga tgcctctggg aacttgggtc ctctggagga
1981 tgtccacatc aaaggagaa tcatagacac ttagagccag gtcattgtt ttcagacata
2041 cacaataaaa agtcacgtgc ccattgagge aaaatatatc ttcttttg atgacaaggc
2101 cgctgtgtgt ggcttgaag cttcatcaa tgggaagcac atagttggag agattaaaga
2161 gaaggaagaa gccagcaag agtacctaga agccgtgacc cagggccatg gcgcttacct
2221 gatgagtcag gatgctccgg acgttttct tgtaagtgtt ggaaacttac cccctaaggc
2281 taaggttctt ataaaaatta cctacatcac agaactcagc atcctgggca ctgttggtgt
2341 cttttcatg cccgccacc tagcaccctg gcaacaggac aaggcttga atgaaaacct
2401 tcaggataca gtagagaaga tttgtataaa agaaatagga acaagcaaa gcttctttt
2461 gactatgtct attgagatgc cgtatgtat tgaattcatt ttcatgata cacatgaact
2521 gaaacaaaag cgcacagact gcaagctgt cattagcacc atggaaggca gtccttaga
2581 cagcagtgga tttctctcc acatcggtt gtctgtgcc tatctccaa gaatgtgggt
2641 tgaaaaacat ccagaaaaag aaagcgagge ttgcatgctt gtcttcaac ccgatctga
2701 tgtcgacctc cctgacctag ccagtgagag cgaagtgtt attgtcttg actgctccag

20/20

2761 ttccatggag ggtgtgacat tcttgcaagc caagcaaate accttgcatt cgctgtcctt
2821 ggtgggtgag aagcagaaag taaatattat ccagttcggc acaggttaca aggagctatt
2881 ttcgtatcct aagcatatca caagcaatac cacggcagca gagttcatca tgtctgccac
2941 acctaccatg gggaacacag acttctggaa aacactccga tatcttagct tattgtaccc
3001 tgctcgaggg tcacggaaca tcttctggt gtctgatggg cacctccagg atgagagcct
3061 gacattacag ctctgaaga ggagccgccc gcacaccagg ttattgcct gcggtatcgg
3121 ttctacagca aatcgtcacg tcttaaggat ttgtcccag tgtggtgccg gattattga
3181 atattttaat gcaaaatcca agcatagttg gagaaaacag atagaagacc aatgaccag
3241 gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc
3301 gcccagaggcc ctgcaggccc cagcccaggt gccatccttg ttctgcaatg atcgactcct
3361 tgtctatgga ttatttctc actgcacaca agcaactctg tgtgcactaa ttcaagagaa
3421 agaattttgt acaatggtgt cgactactga gcttcagaag acaactggaa ctatgatcca
3481 caagctggca gcccagctc taatcagaga ttatgaagat ggcattcttc acgaaaatga
3541 aaccagtcat gagatgaaaa acaaacctt gaaatctctg attattaaac tcagtaaaga
3601 aaactctctc ataacacaat ttacaagctt tgtggcagtt gagaaaaggg atgagaatga
3661 gtgcctttt cctgatattc caaaagttc tgaactatt gccaaagaag atgtagactt
3721 cctgccctac atgagctggc aggggggagcc ccaagaagcc gtcaggaacc agtctctttt
3781 agcatcctct gattggccag aattacgttt atccaaacga aaacatagga aaattccatt
3841 ttccaaaaga aaaatggaat tatctcagcc agaagttct gaagattttg aagaggatgg
3901 cttaggtgta ctaccagctt tcacatcaa ttggaacgt ggaggtgtgg aaaagctatt
3961 ggatttaagt tggacagagt catgtaaacc aacagcaact gaaccactat ttaagaaagt
4021 cagtccatgg gaaacatcta cttctagctt ttctctatt ttggctccgg ccgttggtc
4081 ctatcttacc ccgactacc gcgtcacag tctgtctcc ttgtctttg cctcatatcg
4141 tcaggtagct agtttcggtt cagctgtctc tcccagacag ttgatgcat ctcaattcag
4201 ccaaggccct gtgcctggca cttgtgctga ctggatcca cagtcggcgt cttgtccac
4261 aggacctccc cagaaccac cttctgcacc ctattgtggc attgttttt caggagctc
4321 attagctct gcacagtctg ctccactgca acatctgga ggctttacta ccaggcctc
4381 tgctggcacc ttccctgagc tggattctcc ccagcttcat ttctctctc ctacagacc
4441 tgatccatc agaggtttg ggtcttatca tccctctgt tactctcct ttattttca
4501 accttccgca gcctctttga ctgccaacct taggctgcca atggcctctg cttacctga
4561 ggctctttgc agtcagtc ccgactaccc agtagatctc tgtcttctag aagaatcagt
4621 aggcagtctc gaaggaagtc gatgtctgt cttgtcttt caaagttctg acacagaaag
4681 tgatgagcta tcagaagtac ttcaagacag ctgctttta caaataaagt gtgatacaaa
4741 agatgacagt atcccgtgt ttctggaatt aaaagaagag gatgaaatag tgtgcacaca
4801 aactggcag gatgtgtgc cttggacaga actcctcagt ctacagacag aggatggctt
4861 ctggaaactt acaccagaac tgggacttat attaatctt aatacaaatg gttgcacag
4921 cttcttaaa caaaaaggca ttcaatctt aggtgtaaaa ggaagagaat gtctcctgga
4981 cctaattgcc acaatgctg tactacagtt tattgcacc aggttggaag aagagggaat
5041 agtgttcaaa tcaatgatga aatggatga ccttctatt tccaggaata ttccctgggc
5101 ttgtaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc
5161 tatctgcca cggttgaac tggggaacga ctgggactct gccaccaagc agttgtggg
5221 actccagccc ataagcactg tgtcccctct tcatagagtc ctccattaca gtcaaggcta
5281 agtcaaatga aactgaattt taaactttt gcattgctt atgtagaaaa taatcaaatg
5341 ataatagata attataatga aacttatta aggtttcatt cagtgtagca attactgtct
5401 ttaaaaatta agtggagaag gaattactt aatcaactaa caagcaataa taaatgaaa
5461 cttaaaataa aaaaaaaaaa aaaaaaaaaa